Test Bank for Introduction to Critical Care Nursing, 5th Edition: Mary Lou Sole

Original price was: $35.00.Current price is: $26.50.

Test Bank for Introduction to Critical Care Nursing, 5th Edition: Mary Lou Sole Digital Instant Download

Category:

Test Bank for Introduction to Critical Care Nursing, 5th Edition: Mary Lou Sole

Product details:

  • ISBN-10 ‏ : ‎ 1416056564
  • ISBN-13 ‏ : ‎ 978-1416056560
  • Author: Sole

Here’s the essential information you need to know in critical care nursing ― all in one concise text! Using a to-the-point, reader friendly approach, Introduction to Critical Care Nursing, 5th Edition, provides authoritative, real-world information on the important concepts of critical care nursing and the assessment and technical skills associated with the management of critically ill patients. The latest content on the technology makes it easy to learn and understand how to use the equipment you’ll use in the field. Nursing care chapters are organized according to the nursing process framework, and you’ll find detailed nursing care plans in every management chapter. Case studies and critical thinking questions challenge you to apply what you’ve learned, and user-friendly features throughout the text (updated pharmacology tables, clinical and laboratory alerts, and evidence-based practice boxes) help you bridge the gap between concepts and clinical practice.

Table contents:

  1. Part I Fundamental Concepts
  2. CHAPTER 1 Overview of Critical Care Nursing
  3. DEFINITION OF CRITICAL CARE NURSING
  4. EVOLUTION OF CRITICAL CARE
  5. PROFESSIONAL ORGANIZATIONS
  6. American Association of Critical-Care Nurses
  7. BOX 1-1 Role of the Critical Care Nurse as Patient Advocate
  8. BOX 1-2 Desired Competencies of Nurses Caring for the Critically Ill
  9. Society of Critical Care Medicine
  10. Other Professional Organizations
  11. CERTIFICATION
  12. STANDARDS
  13. BOX 1-3 Standards of Critical Care Professional Practice
  14. TRENDS AND ISSUES
  15. BOX 1-4 Examples of Patient Safety Goals
  16. BOX 1-5 Interventions to Reduce Harm and Prevent Injury
  17. BOX 1-6 Items to Consider in Daily Multidisciplinary Rounds
  18. SUMMARY
  19. CRITICAL THINKING QUESTIONS
  20. REFERENCES
  21. CHAPTER 2 The Critical Care Experience
  22. INTRODUCTION
  23. THE CRITICAL CARE ENVIRONMENT
  24. TABLE 2-1 Noise Levels Associated with Patient Care Devices and Activities
  25. Critical Care Culture
  26. Communication
  27. BOX 2-1 Elements of the Healthy Work Environment Initiative
  28. FIGURE 2-1 Interdependence of healthy work environment, clinical excellence, and optimal patient outcomes.
  29. BOX 2-2 Barriers to Effective Handoff Communication
  30. Communication Techniques from Industry: Crew Resource Management
  31. BOX 2-3 Situation, Background, Assessment, Recommendation (SBAR)
  32. Collaboration
  33. THE CRITICALLY ILL PATIENT
  34. BOX 2-4 Patients’ Recollection of the Critical Care Experience
  35. Cultural Considerations
  36. TABLE 2-2 Cultural Considerations
  37. Discharge from Critical Care and Quality of Life after Critical Care
  38. Geriatric Concerns
  39. FAMILY MEMBERS OF THE CRITICALLY ILL PATIENT
  40. EVIDENCE-BASED PRACTICE
  41. PROBLEM
  42. QUESTION
  43. REFERENCE
  44. EVIDENCE
  45. DECISION MAKING
  46. FAMILY COPING
  47. STAFF STRESS
  48. CULTURAL SUPPORT OF FAMILY
  49. SPIRITUAL AND RELIGIOUS SUPPORT
  50. FAMILY VISITATION
  51. FAMILY ENVIRONMENT OF CARE
  52. FAMILY PRESENCE DURING ROUNDS
  53. FAMILY PRESENCE DURING RESUSCITATION
  54. PALLIATIVE CARE
  55. IMPLICATIONS FOR NURSING
  56. Family Assessment
  57. Family Needs
  58. Visitation
  59. Family Presence during Procedures and Resuscitation
  60. BOX 2-5 Benefits of Family Presence
  61. THE CRITICAL CARE NURSE
  62. AACN SYNERGY MODEL FOR PATIENT CARE
  63. TABLE 2-3 American Association of Critical-Care Nurses Synergy Model Nurse Competencies
  64. BOX 2-6 American Association of Critical-Care Nurses Synergy Model Patient Characteristics
  65. SUMMARY
  66. CRITICAL THINKING QUESTIONS
  67. REFERENCES
  68. CHAPTER 3 Ethical and Legal Issues in Critical Care Nursing
  69. INTRODUCTION
  70. ETHICAL OBLIGATIONS AND NURSE ADVOCACY
  71. ETHICAL DECISION MAKING
  72. ETHICAL PRINCIPLES
  73. FIGURE 3-1 The process of ethical decision making.
  74. BOX 3-1 Ethical Principles
  75. Moral Theories
  76. INCREASING NURSES’ INVOLVEMENT IN ETHICAL DECISION MAKING
  77. TABLE 3-1 Moral Theories
  78. BOX 3-2 Situations Where Ethics Consultation May Be Considered
  79. BOX 3-3 Ethics Consultation Services
  80. BOX 3-4 Internet Resources for Bioethics
  81. LEGAL ACCOUNTABILITY IN NURSING
  82. Licensure and Mandatory Education
  83. Criminal Lawsuits
  84. Medical Malpractice
  85. Duty to Treat and Abandonment
  86. SELECTED ETHICAL AND LEGAL ISSUES
  87. Informed Consent
  88. Elements of Informed Consent
  89. Informed Consent of Adolescents
  90. Decisions Regarding Life-Sustaining Treatment
  91. TABLE 3-2 Landmark Legal Cases in the Right-to-Die Debate
  92. BOX 3-5 Definitions in Critical Care Decision Making
  93. Cardiopulmonary Resuscitation Decisions
  94. Withholding or Withdrawal of Life Support
  95. End-of-Life Issues
  96. Patient Self-Determination Act
  97. Advance Directives
  98. Organ and Tissue Transplantation
  99. TABLE 3-3 Organ and Tissue Transplantation
  100. BOX 3-6 Criteria Used to Determine Brain Death*
  101. Ethical Concerns Surrounding Transplantation
  102. CASE STUDY
  103. QUESTIONS
  104. SUMMARY
  105. CRITICAL THINKING QUESTIONS
  106. REFERENCES
  107. CHAPTER 4 End-of-Life Care in the Critical Care Unit
  108. INTRODUCTION
  109. ETHICAL AND LEGAL CONCERNS
  110. BOX 4-1 Definition of Medical Futility
  111. Effects on Nurses and the Health Care Team
  112. DIMENSIONS OF END-OF-LIFE CARE
  113. Palliative Care
  114. Communication and Conflict Resolution
  115. Withholding, Limiting, or Withdrawing Therapy
  116. BOX 4-2 Guidelines for Effective Communication to Facilitate End-of-Life Care
  117. BOX 4-3 Ethical Principles for Withholding and Withdrawing Life-Sustaining Treatment
  118. Ventilator Withdrawal
  119. CLINICAL ALERT
  120. Ventilator Withdrawal
  121. Other Commonly Withheld Therapies
  122. Emotional and Psychological Care of the Patient/Family
  123. FIGURE 4-1 Guidelines for pharmacological interventions during withdrawal of life support.
  124. EVIDENCE-BASED PRACTICE
  125. PROBLEM
  126. QUESTIONS
  127. REFERENCE
  128. EVIDENCE
  129. IMPLICATIONS FOR NURSING
  130. Caregiver Organizational Support
  131. BOX 4-4 Nursing Interventions to Support Care at the End of Life
  132. CULTURALLY COMPETENT END-OF-LIFE CARE
  133. BOX 4-5 End-of-Life Online Resources
  134. CASE STUDY
  135. QUESTIONS
  136. SUMMARY
  137. CRITICAL THINKING QUESTIONS
  138. REFERENCES
  139. Part II Tools for the Critical Care Nurse
  140. CHAPTER 5 Comfort and Sedation
  141. INTRODUCTION
  142. DEFINITIONS OF PAIN AND ANXIETY
  143. FIGURE 5-1 The anxiety-pain cycle.
  144. Box 5-1 Gate Control Theory of Pain
  145. PREDISPOSING FACTORS TO PAIN AND ANXIETY
  146. PHYSIOLOGY OF PAIN AND ANXIETY
  147. Pain
  148. TABLE 5-1 Physiological Responses to Pain and/or Anxiety
  149. FIGURE 5-2 Transmission of pain signals into the brainstem, thalamus, and cerebral cortex by way of the “fast” pain pathway and “slow” pain pathway.
  150. TABLE 5-2 Neuroimaging Studies
  151. Anxiety
  152. POSITIVE EFFECTS OF PAIN AND ANXIETY
  153. NEGATIVE EFFECTS OF PAIN AND ANXIETY
  154. Physical Effects
  155. Psychological Effects
  156. ASSESSMENT
  157. Pain Measurement Tools
  158. Pain Measurement Tools for Nonverbal Patients
  159. Adult Behavioral Pain Tools
  160. FIGURE 5-3 A version of the FACES scale.
  161. FIGURE 5-4 The Visual Analog Scale.
  162. TABLE 5-3 The Behavioral Pain Scale*
  163. Pediatric Pain Tools
  164. TABLE 5-4 Critical-Care Pain Observation Tool
  165. TABLE 5-5 The FLACC Scale
  166. Anxiety and Sedation Measurement Tools
  167. Sedation Scales
  168. Continuous Monitoring of Sedation
  169. TABLE 5-6 Richmond Agitation-Sedation Scale
  170. FIGURE 5-5 The Bispectral Index (BIS) monitor and electrode.
  171. TABLE 5-7 The Ramsay Sedation Scale
  172. TABLE 5-8 Sedation-Agitation Scale
  173. PAIN AND ANXIETY ASSESSMENT CHALLENGES
  174. Delirium
  175. TABLE 5-9 Clinical Subtypes of Delirium
  176. TABLE 5-10 Risk Factors for Delirium
  177. BOX 5-2 The Confusion Assessment Method for the Critical Care Unit
  178. Neuromuscular Blockade
  179. EVIDENCE-BASED PRACTICE
  180. PROBLEM
  181. QUESTIONS
  182. REFERENCE
  183. EVIDENCE
  184. IMPLICATIONS FOR NURSING
  185. FIGURE 5-6 A train-of-four peripheral nerve stimulator.
  186. BOX 5-3 Nursing Care of the Patient Receiving Neuromuscular Blockade
  187. MANAGEMENT OF PAIN AND ANXIETY
  188. Nonpharmacological Management
  189. Environmental Manipulation
  190. TABLE 5-11 PHARMACOLOGY Drugs Frequently Used in the Treatment of Anxiety, Pain, or for Neuromuscular Blockade*
  191. Guided Imagery
  192. Music Therapy
  193. Pharmacological Management
  194. Opioids
  195. CLINICAL ALERT
  196. Cautions in Use of Cyclooxygenase-2 (COX-2) Inhibitors and NSAIDs
  197. FIGURE 5-7 A patient-controlled analgesia infusion pump.
  198. Patient-Controlled Analgesia
  199. BOX 5-4 Typical Patient Criteria for Patient-Controlled Analgesia Therapy
  200. Epidural Analgesia
  201. BOX 5-5 Potential Benefits of Epidural Analgesia
  202. Nonsteroidal Antiinflammatory Drugs
  203. Sedative Agents
  204. Tolerance and Withdrawal
  205. MANAGEMENT CHALLENGES
  206. Invasive Procedures
  207. FIGURE 5-8 Sample algorithm of sedation guidelines.
  208. Substance Abuse
  209. FIGURE 5-9 The Cleveland Clinic Foundation Procedural Sedation Record: Nursing Assessment Page.
  210. Restraining Devices
  211. Effects of Aging
  212. TABLE 5-12 Common Restraining Devices
  213. GERIATRIC CONSIDERATIONS
  214. CASE STUDY
  215. QUESTIONS
  216. SUMMARY
  217. CRITICAL THINKING QUESTIONS
  218. REFERENCES
  219. CHAPTER 6 Nutritional Support
  220. INTRODUCTION
  221. GASTROINTESTINAL TRACT
  222. UTILIZATION OF NUTRIENTS
  223. ASSESSMENT OF NUTRITIONAL STATUS
  224. GERIATRIC CONSIDERATIONS
  225. OVERVIEW OF NUTRITIONAL SUPPORT
  226. Enteral Nutrition
  227. Parenteral Nutrition
  228. EVIDENCE-BASED PRACTICE
  229. PROBLEM
  230. QUESTION
  231. REFERENCE
  232. EVIDENCE
  233. IMPLICATIONS FOR NURSING
  234. Nutritional Additives
  235. NUTRITIONAL THERAPY GOAL
  236. TABLE 6-1 Components of Immune-Enhancing Formulas
  237. TABLE 6-2 Estimation of Nutrient Needs
  238. TABLE 6-3 Enteral Formulas
  239. PRACTICE GUIDELINES
  240. Enteral Nutrition
  241. Parenteral Nutrition
  242. Drug-Nutrient Interactions
  243. Monitoring Nutritional Status and Monitoring for Complications
  244. TABLE 6-4 Tube Feeding Complications and Nursing Interventions
  245. CLINICAL ALERT
  246. Assessment of Feeding Tube Placement
  247. LABORATORY ALERT
  248. MONITORING AND EVALUATING THE NUTRITION CARE PLAN
  249. CASE STUDY
  250. QUESTIONS
  251. SUMMARY
  252. CRITICAL THINKING QUESTIONS
  253. REFERENCES
  254. CHAPTER 7 Dysrhythmia Interpretation and Management
  255. INTRODUCTION
  256. BASIC ELECTROPHYSIOLOGY
  257. Automaticity
  258. The Cardiac Cycle
  259. Cardiac Action Potential
  260. FIGURE 7-1 Cardiac action potential with the electrocardiogram and movement of electrolytes. ATP, Adenosine triphosphate; Ca, calcium; K, potassium; Na, sodium.
  261. Relationship Between Electrical Activity and Muscular Contraction
  262. PHARMACOLOGY TABLE 7-1 Antidysrhythmic Drug Classifications
  263. CLINICAL ALERT
  264. Antidysrhythmic Drugs
  265. Normal Cardiac Conduction Pathway
  266. FIGURE 7-2 The electrical conduction system of the heart. Arrows indicate direction of electrical currents. The ECG represents the net sum of these currents. RA, Right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle.
  267. THE 12-LEAD ELECTROCARDIOGRAPHY SYSTEM
  268. Standard Limb Leads
  269. Augmented Limb Leads
  270. FIGURE 7-3 Orientation of leads I, II, and III. Lead I records the difference in electrical potentials between the left arm and right arm. Lead II records it between the left leg and right arm. Lead III records it between the left leg and left arm.
  271. FIGURE 7-4 A, Einthoven’s triangle. B, The triangle is converted to a triaxial diagram by shifting leads I, II, III that they intersect at a common point.
  272. FIGURE 7-5 Triaxial lead diagram showing the relationship of the three augmented (unipolar) leads aVR, aVL, and aVF. Notice that each lead is represented by an axis with a positive and negative pole. The term unipolar was used to mean that the leads record the voltage in one location relative to about zero potential instead of relative to the voltage in one other extremity.
  273. Precordial Leads
  274. FIGURE 7-6 The precordial leads. The positive poles of the chest leads point anteriorly and the negative poles (dashed lines) point posteriorly.
  275. FIGURE 7-7 Limb leads and V1 electrode placement and their respective waveforms: A, Lead I; B, lead II; C, lead III; and D, lead V1.
  276. Continuous Cardiac Monitoring
  277. TABLE 7-2 Recommended Electrocardiographic Monitoring Leads for Specific Clinical Incidents
  278. FIGURE 7-8 Lead placement when using a five-lead cable. The chest lead is shown in the V1 position.
  279. TABLE 7-3 Indications for Cardiac Dysrhythmia Monitoring3
  280. ANALYZING THE BASIC ELECTROCARDIOGRAPHIC TRACING
  281. Measurements
  282. FIGURE 7-9 The ECG is usually recorded on a graph divided into millimeter squares, with darker lines marking 5-mm squares. Time is measured on the horizontal axis. With a paper speed of 25 mm/sec, each small (1-mm) box side equals 0.04 second and each larger (5-mm) box side equals 0.2 second. The amplitude of any wave is measured in millimeters on vertical axis.
  283. Waveforms and Intervals
  284. P Wave
  285. FIGURE 7-10 The P wave represents atrial depolarization. The PR interval is the time from initial stimulation of the atria to initial stimulation of the ventricles. The QRS represents ventricular depolarization. The ST segment, T wave, and U wave are produced by ventricular depolarization.
  286. PR Interval
  287. QRS Complex
  288. FIGURE 7-11 A, A positive complex is seen in any lead if the wave of depolarization spreads toward the positive pole of the lead. B, A negative complex is seen if the depolarization wave spreads toward the negative pole (away from the positive pole) of the lead. C, A biphasic (partly positive, partly negative) complex is seen if the mean direction of the wave is at right angles. These apply to the P wave, QRS, and T wave.
  289. FIGURE 7-12 Different types of QRS complexes. An R wave is a positive waveform. A negative deflection before the R wave is a Q wave. The S wave is a negative deflection after the R wave. If the waveform is tall or deep, the letter naming the waveform is a capital letter. If the waveform is small in either direction, the waveform is labeled with a lower case letter.
  290. QRS Interval
  291. FIGURE 7-13 Pathological Q wave (abnormal Q wave) 0.04 seconds wide and at least one fourth the height of the R wave.
  292. T Wave
  293. ST Segment
  294. QT Interval
  295. FIGURE 7-14 A, Step-by-step sequence of ventricular depolarization in right bundle branch block. B, The sequence of ventricular depolarization in left bundle branch block produces a wide QS complex in lead V1 and a wide R wave in lead V6. LV, Left ventricle; RV, right ventricle.
  296. CLINICAL ALERT
  297. ST Segment Monitoring Practice for Ischemia2
  298. FIGURE 7-15 Abnormal QT interval prolongation in patient taking quinidine. The QT interval (0.6 seconds) is markedly prolonged for the heart rate (65/min) and the QT interval is greater than one half the R-R interval.
  299. CLINICAL ALERT
  300. QT Interval and ECG Monitoring for Detection of Proarrhythmias2
  301. Box 7-1 Systematic Approach for Rhythm Interpretation
  302. SYSTEMATIC INTERPRETATION OF DYSRHYTHMIAS
  303. Rhythmicity
  304. FIGURE 7-16 Establishing ventricular rhythmicity with calipers.
  305. FIGURE 7-17 Establishing ventricular rhythmicity with paper and pencil.
  306. Rate
  307. FIGURE 7-18 Calculating ventricular rate with the rule of 1500. Count the number of small boxes between QRS complexes. In this strip there are 15 small squares between QRS complexes; 1500 divided by 15 equals a heart rate of 100.
  308. Waveform Configuration and Location
  309. Configuration
  310. Location
  311. Intervals
  312. Basic Dysrhythmias
  313. Normal Sinus Rhythm
  314. FIGURE 7-19 Normal sinus rhythm. Rhythm strip generated by the AA-700 Rhythm Simulator.
  315. FIGURE 7-20 Sinus tachycardia.
  316. Critical Criteria for Diagnosis of Normal Sinus Rhythm
  317. Hemodynamic Effects.
  318. Dysrhythmias of the Sinoatrial Node
  319. Sinus Tachycardia
  320. Exercise.
  321. Stimulants.
  322. Increased Body Temperature.
  323. Alterations in Fluid Status.
  324. Critical Criteria for Diagnosis of Sinus Tachycardia
  325. Hemodynamic Effects.
  326. Sinus Bradycardia
  327. Bradycardia as a Normal Finding.
  328. Increased Vagal Stimulation.
  329. Drug Effects.
  330. SA Node Ischemia.
  331. Effects of Hypoxemia.
  332. Increased Intracranial Pressure.
  333. Critical Criteria for Diagnosis of Sinus Bradycardia
  334. Hemodynamic Effects.
  335. Box 7-2 Categories of Drugs
  336. Box 7-3 Symptoms of Decreased Cardiac Output
  337. FIGURE 7-21 Sinus bradycardia. Notice the negative P waves and QRS because this is lead aVR.
  338. Sinus Dysrhythmia
  339. Critical Criteria for Diagnosis of Sinus Dysrhythmia
  340. Hemodynamic Effects.
  341. Sinus Pauses and Sinus Arrest
  342. Enhanced Vagal Tone.
  343. FIGURE 7-22 Sinus dysrhythmia. Normally, the heart rate increases slightly with inspiration and decreases slightly with expiration.
  344. FIGURE 7-23 Sinus arrest/sinus exit block. Note the junctional escape beat at the end of the pause.
  345. Coronary Artery Disease.
  346. Effects of Drugs.
  347. Critical Criteria for Diagnosis of Sinus Arrest and Sinus Exit Block
  348. Hemodynamic Effects.
  349. Dysrhythmias of the Atria
  350. Stress.
  351. Electrolyte Imbalances.
  352. Hypoxemia.
  353. Injury to the Atria.
  354. Digitalis Toxicity.
  355. Hypothermia.
  356. Hyperthyroidism.
  357. Alcohol Intoxication.
  358. Pericarditis.
  359. Premature Atrial Contractions
  360. FIGURE 7-24 Premature atrial contractions shown in the fifth and seventh beats. The P wave occurs on the T wave for these premature atrial contractions.
  361. Critical Criteria for Diagnosis of Premature Atrial Contractions
  362. Critical Criteria for Diagnosis of Blocked Premature Atrial Contractions
  363. Hemodynamic Effects.
  364. Atrial Tachycardia
  365. FIGURE 7-25 Compensatory pause. PVC, Premature ventricular contraction.
  366. Box 7-4 Compensatory versus Noncompensatory Pause
  367. FIGURE 7-26 A, The fifth beat is an atrial premature contraction. B, Blocked premature atrial contraction (PAC).
  368. Box 7-5 Supraventricular Tachycardia
  369. FIGURE 7-27 Notice the marked regularity of rhythm in this paroxysmal supraventricular tachycardia (PSVT). The rate is 170 beats per minute.
  370. Critical Criteria for Diagnosis of Atrial Tachycardia
  371. Hemodynamic Effects.
  372. Wolff-Parkinson with Preexcitation Patterns (Figure 7-29)
  373. Wandering Atrial Pacemaker
  374. FIGURE 7-28 A, Normal sinus rhythm. B, With atrial tachycardia (AT), a focus (X) outside the sinoatrial (SA) node fires off automatically at a rapid rate. C, With atrioventricular (AV) nodal reentrant tachycardia (AVNRT), the cardiac stimulus originates as a wave of excitation that spins around the AV nodal (junctional) area. As a result, retrograde P waves may be buried in the QRS or appear immediately before or just after the QRS complex (arrows) because of nearly simultaneous activation of the atria and ventricles. D, A similar type of reentrant (circus movement) mechanism in Wolff-Parkinson-White syndrome. This mechanism is referred to as atrioventricular reentrant tachycardia (AVRT). Note the P wave in lead II somewhat after the QRS complex.
  375. Critical Criteria for Diagnosis of Wandering Atrial Pacemaker
  376. Hemodynamic Effects.
  377. Multifocal Atrial Tachycardia
  378. FIGURE 7-29 Preexcitation via the bypass tract in the Wolff-Parkinson White (WPW) pattern is associated with a triad finding.
  379. FIGURE 7-30 Wandering atrial pacemaker. Note the varying P-wave morphologies.
  380. Critical Criteria for Diagnosis of Multifocal Atrial Tachycardia
  381. Hemodynamic Effects.
  382. Atrial Flutter
  383. FIGURE 7-31 Multifocal atrial tachycardia.
  384. Critical Criteria for Diagnosis of Atrial Flutter
  385. Hemodynamic Effects.
  386. Atrial Fibrillation
  387. FIGURE 7-32 Atrial flutter with a fixed degree of block. Note the sawtooth configuration and the negative orientation of the flutter waves. Rhythm generated by the AA-700 Rhythm Simulator.
  388. FIGURE 7-33 Atrial flutter with varying degrees of block.
  389. FIGURE 7-34 Atrial fibrillation.
  390. FIGURE 7-35 Aberrancy is most likely to result when the right bundle branch blocks. The impulse must depolarize the left side of the heart first. The impulse then crosses the septum and abnormally depolarizes the right side of the heart. This results in a widened QRS complex.
  391. EVIDENCE-BASED PRACTICE
  392. PROBLEM
  393. REFERENCE
  394. QUESTION
  395. EVIDENCE
  396. IMPLICATIONS FOR NURSING
  397. Critical Criteria for Diagnosis of Atrial Fibrillation
  398. FIGURE 7-36 Atrial fibrillation. Note Ashman’s beat, following a long-short cycle.
  399. CLINICAL ALERT
  400. Hemodynamic Effects.
  401. Dysrhythmias of the Atrioventricular Node
  402. Junctional Rhythm
  403. P-Wave Changes.
  404. FIGURE 7-37 Junctional (nodal) rhythm. Note absence of P waves.
  405. FIGURE 7-38 Junctional (nodal) rhythm. Note the inverted P wave and the shortened PR interval.
  406. FIGURE 7-39 Junctional (nodal) rhythm. Note the P waves after the QRS complex.
  407. Critical Criteria for Diagnosis of Junctional Rhythm
  408. Hemodynamic Effects.
  409. Accelerated Junctional Rhythm and Junctional Tachycardia
  410. Critical Criteria for Diagnosis of Accelerated Junctional and Junctional Tachycardia
  411. Hemodynamic Effects.
  412. Premature Junctional Contractions
  413. FIGURE 7-40 Junctional tachycardia. Note the short PR interval and heart rate of 70 beats per minute. Rhythm generated by the AA-700 Rhythm Simulator.
  414. FIGURE 7-41 Premature junctional contractions. A, Third beat with a shortened PR interval and an inverted P wave. B, Fourth beat, no P waves visible. C, Third beat with a retrograde P wave.
  415. Critical Criteria for Diagnosis of Premature Junctional Contractions
  416. Hemodynamic Effects.
  417. Dysrhythmias of the Ventricle
  418. FIGURE 7-42 Unifocal premature ventricular contractions.
  419. Myocardial Ischemia, Injury, and Infarction.
  420. Hypokalemia.
  421. Hypomagnesemia.
  422. Hypoxemia.
  423. Acid-Base Imbalances.
  424. Premature Ventricular Contractions
  425. FIGURE 7-43 Multifocal premature ventricular contractions. Note the compensatory pause.
  426. FIGURE 7-44 Premature ventricular contractions in a bigeminal pattern. Rhythm strip generated by the AA-700 Rhythm Simulator.
  427. FIGURE 7-45 Two premature ventricular contractions in a row (pair).
  428. FIGURE 7-46 Three premature ventricular contractions in a row (triplet).
  429. FIGURE 7-47 A, R-on-T phenomenon in a patient with an acute myocardial infarction. B, In the same patient, the R-on-T phenomenon causes ventricular fibrillation.
  430. Critical Criteria for Diagnosis of Premature Ventricular Contractions
  431. Hemodynamic Effects.
  432. Ventricular Tachycardia
  433. FIGURE 7-48 Ventricular tachycardia. Rhythm strip generated by the AA-700 Rhythm Simulator.
  434. Critical Criteria for Diagnosis of Ventricular Tachycardia
  435. Hemodynamic Effects.
  436. Ventricular Fibrillation
  437. Critical Criteria for Diagnosis of Ventricular Fibrillation
  438. Hemodynamic Effects.
  439. Idioventricular Rhythm
  440. FIGURE 7-49 Fine ventricular fibrillation.
  441. FIGURE 7-50 Coarse ventricular fibrillation.
  442. FIGURE 7-51 Idioventricular rhythm.
  443. Critical Criteria for Diagnosis of Idioventricular Rhythm
  444. Hemodynamic Effects.
  445. Accelerated Idioventricular Rhythm
  446. Critical Criteria for Diagnosis of Accelerated Idioventricular Rhythm
  447. Hemodynamic Effects.
  448. FIGURE 7-52 Accelerated idioventricular rhythm.
  449. FIGURE 7-53 Ventricular standstill or asystole.
  450. Ventricular Standstill (Asystole)
  451. Critical Criteria for Diagnosis of Ventricular Standstill (Asystole)
  452. Hemodynamic Effects.
  453. Atrioventricular Blocks
  454. Coronary Artery Disease.
  455. Infectious and Inflammatory Processes.
  456. Enhanced Vagal Tone.
  457. Effects of Drugs.
  458. First-Degree Block
  459. Critical Criteria for the Diagnosis of First-Degree Block
  460. Hemodynamic Effects.
  461. Second-Degree Block
  462. GERIATRIC CONSIDERATIONS
  463. Second-Degree Block Type I: Mobitz I or Wenckebach’s Phenomenon
  464. Critical Criteria for Diagnosis of Second-Degree Block Type I
  465. Hemodynamic Effects.
  466. Second-Degree Block Type II: Mobitz II
  467. FIGURE 7-54 First-degree block. Rhythm strip generated by the AA-700 Rhythm Simulator.
  468. FIGURE 7-55 Second-degree block, Mobitz type I, or Wenckebach’s phenomenon. Note the steadily lengthening PR interval. Rhythm strip generated by the AA-700 Rhythm Simulator.
  469. FIGURE 7-56 Second-degree block, Mobitz type II. Note the fixed PR interval. Rhythm strip generated by the AA-700 Rhythm Simulator.
  470. Critical Criteria for Diagnosis of Second-Degree Block Type II
  471. Hemodynamic Effects.
  472. Third-Degree Block (Complete Heart Block)
  473. Critical Criteria for Diagnosis of Third-Degree Block (Complete Heart Block)
  474. FIGURE 7-57 Third-degree block with ventricular escape. Rhythm strip generated by the AA-700 Rhythm Simulator.
  475. Hemodynamic Effects.
  476. INTERVENTIONS FOR DYSRHYTHMIAS
  477. Tachydysrhythmias
  478. Bradydysrhythmias
  479. ELECTRICAL PACEMAKERS
  480. Rate.
  481. Mode.
  482. Electrical Output.
  483. Sensitivity.
  484. AV Internal.
  485. Pacemaker Rhythms.
  486. Pacemaker Malfunction.
  487. Failure to Pace.
  488. FIGURE 7-58 Paced rhythm: atrial. Note the spike in front of the P wave. Rhythm strip generated by the AA-700 Rhythm Simulator.
  489. FIGURE 7-59 Paced rhythm: ventricular. Note the spike in front of the QRS complex. Rhythm strip generated by the AA-700 Rhythm Simulator.
  490. FIGURE 7-60 Paced rhythm: dual chamber. Note the spikes before the P wave and the QRS complex. Rhythm strip generated by the AA-700 Rhythm Simulator.
  491. Failure to Capture.
  492. Failure to Sense.
  493. FIGURE 7-61 Paced rhythm with failure to capture.
  494. FIGURE 7-62 Paced rhythm with failure to capture (seventh spike) and failure to sense, note arrow (eighth spike).
  495. Biventricular Pacemaker
  496. FIGURE 7-63 Biventricular pacing with wires of the right atrium/ventricle and left ventricle.
  497. FIGURE 7-64 Patient’s actual rhythm (top strip, note the wide QRS). Biventricular pacing of right and left ventricle (bottom strip, note the QRS is not as wide as the top strip).
  498. NURSING CARE PLAN
  499. NURSING DIAGNOSIS
  500. PATIENT OUTCOMES
  501. Maintains optimal cardiac output
  502. CASE STUDY
  503. QUESTIONS
  504. SUMMARY
  505. CRITICAL THINKING QUESTIONS
  506. REFERENCES
  507. CHAPTER 8 Hemodynamic Monitoring
  508. INTRODUCTION
  509. REVIEW OF ANATOMY AND PHYSIOLOGY
  510. Cardiovascular System Structure
  511. Heart
  512. Arteries
  513. Capillaries
  514. FIGURE 8-1 Diagram of the cardiovascular system.
  515. Veins
  516. FIGURE 8-2 Cardiac cycle.
  517. Blood
  518. Principles of Physics
  519. FIGURE 8-3 Relationship between vessel diameter, flow, and resistance. A, Effect of lumen diameter on flow through vessel. d, Diameter. B, Blood flows with great speed in the large arteries. However, branching of arterial vessels increases the total cross-sectional areas of the arterioles and capillaries, thus reducing the flow rate.
  520. Components of Cardiac Output
  521. FIGURE 8-4 Cardiac output components. Cardiac output is determined by heart rate and stroke volume.
  522. FIGURE 8-5 Normal blood flow through the heart and intrachamber pressures; arrows indicate the normal direction of blood flow. This schematic representation of the heart shows all four chambers and valves visible in the anterior view to facilitate conceptualization of blood flow.
  523. Regulation of Cardiovascular Function
  524. Effects of Aging
  525. FIGURE 8-6 Factors regulating blood flow.
  526. HEMODYNAMIC MONITORING MODALITIES
  527. FIGURE 8-7 Impact of age-related changes on cardiac function.
  528. Noninvasive Monitoring
  529. Noninvasive Blood Pressure
  530. Jugular Venous Pressure
  531. Lactate
  532. TABLE 8-1 Normal Hemodynamic Values
  533. Invasive Hemodynamic Monitoring
  534. Indications
  535. BOX 8-1 Indications for Invasive Hemodynamic Monitoring
  536. Arterial Lines
  537. Central Venous Catheter
  538. Pulmonary Artery Catheter
  539. FIGURE 8-8 Assessment of jugular venous pressure:1.Place the patient in a supine position with the head of bed elevated 30 to 45 degrees.2.Position yourself at the patient’s right side.3.Have the patient turn head slightly to the left.4.If you cannot readily identify the jugular vein, place light pressure with your fingertips across the sternocleidomastoid muscle just superior and parallel to the clavicle. This pressure obstructs the external jugular vein and allows it to fill. Shine a pen light tangentially across the neck to accentuate the pulsations.5.Assess for jugular venous distention at end exhalation.6.Any fullness in the vein extending >3 cm above the sternal angle or angle of Louis is considered elevated jugular venous pressure. The higher the degree of elevation, the higher the central venous pressure.7.Observe the highest point of pulsation in the internal jugular vein at end exhalation.8.Measure the vertical distance between this pulsation and the angle of Louis in centimeters.9.Add 5 cm to this number for an estimation of central venous pressure.10.Normal is 7 to 9 cm.
  540. Equipment Common to All Intravascular Monitoring
  541. BOX 8-2 Complications of Invasive Hemodynamic Monitoring Devices
  542. FIGURE 8-9 Components of an invasive monitoring system connected to one flush solution. A, Invasive catheter. B, Noncompliant pressure tubing. C, Transducer and zeroing stopcock. D, Pressurized flush system. E, Bedside monitoring system. (Not to scale)
  543. Nursing Implications
  544. FIGURE 8-10 Example of a triple-lumen central line to measure central venous pressure and oxygen saturation.
  545. FIGURE 8-11 Example of a pulmonary artery catheter with capability of monitoring mixed venous oxygenation.
  546. FIGURE 8-12 A schematic of a typical pressure transducer.
  547. Leveling the Air-Fluid Interface (Zeroing Stopcock)
  548. FIGURE 8-13 Locating the phlebostatic axis in the supine position.
  549. Patient Position
  550. CLINICAL ALERT
  551. Hemodynamic Monitoring
  552. FIGURE 8-14 A, Optimal Dynamic Response Test. B, Overdamped Dynamic Response Test. C, Underdamped Dynamic Response Test.
  553. Zero Referencing
  554. Dynamic Response Testing
  555. BOX 8-3 Abnormal Dynamic Response Test: Causes and Interventions
  556. Overdamped system
  557. Underdamped system
  558. Infection Control
  559. BOX 8-4 General Nursing Strategies for Managing Hemodynamic Monitoring Systems
  560. Arterial Pressure Monitoring
  561. BOX 8-5 Allen’s and Modified Allen’s Test Procedure
  562. Allen’s Test
  563. Modified Allen’s Test
  564. Complications
  565. FIGURE 8-15 A, Normal arterial pressure tracing; 1, peak systolic pressure; 2, dicrotic notch; 3, diastolic pressure; 4, anacrotic notch. B, Arterial pressure waveform obtained from arterial line.
  566. Clinical Considerations
  567. BOX 8-6 Causes of Higher Noninvasive versus Invasive Blood Pressure
  568. Nursing Implications
  569. Right Atrial Pressure/Central Venous Pressure Monitoring
  570. FIGURE 8-16 Position of central venous catheter in right atrium along with associated waveforms.
  571. Complications
  572. FIGURE 8-17 Identifying the a, c, and v waveforms to determine right atrial pressure.
  573. BOX 8-7 Methods for Determining Accurate Right Atrial Pressure
  574. Pre-c method
  575. Mean of the a waves
  576. Z-point method
  577. Clinical Considerations
  578. Nursing Implications
  579. Pulmonary Artery Pressure Monitoring
  580. FIGURE 8-18 A five-lumen pulmonary artery (PA) catheter containing the four-lumen components in addition to a second proximal lumen for infusion of fluid or medications.
  581. Hemodynamic Parameters Monitored via the PAC
  582. FIGURE 8-19 Position of pulmonary artery (PA) catheter and associated waveforms. (A) Dual-channel tracing of cardiac rhythm with pressure waveforms obtained as the PA catheter is inserted into the right atrium (RA) and right ventricle (RV); (B) dual-channel tracing of cardiac rhythm with RV, PA, and pulmonary artery occlusion pressure (PAOP) waveforms as the catheter is floated into proper position; (C), PA catheter in pulmonary artery; (D) PA catheter floating into pulmonary capillary with balloon inflated for PAOP measurements.
  583. Clinical Considerations
  584. FIGURE 8-20 Effect of respiration on pulmonary artery waveforms in patients with spontaneous breathing (A) and mechanical ventilation (B).
  585. Nursing Implications
  586. Controversy Surrounding the PAC
  587. Cardiac Output Monitoring
  588. Thermodilution Cardiac Output
  589. BOX 8-8 Interpretation of Abnormal Cardiac Output/Index Values
  590. Low Cardiac Output/Index
  591. High Cardiac Output/Index
  592. EVIDENCE-BASED PRACTICE
  593. PROBLEM
  594. QUESTION
  595. REFERENCES
  596. EVIDENCE
  597. Implications for Nursing
  598. Continuous Cardiac Output
  599. FIGURE 8-21 Illustration of the closed injectate delivery system (room temperature fluids) for thermodilution cardiac output measurement.
  600. FIGURE 8-22 Illustration of injection of fluid into the right atrium (RA) for cardiac output measurement.
  601. BOX 8-9 Steps to Ensure Accurate Thermodilution Cardiac Output Measurements
  602. Oxygen Delivery and Consumption
  603. FIGURE 8-23 A sample monitor interface displaying hemodynamic parameters and trends, including continuous cardiac output (CCO) and mixed venous oxygen saturation (SvO2).
  604. TABLE 8-2 Hemodynamic Calculations
  605. TABLE 8-3 Alterations in Mixed Venous Oxygen Saturation
  606. BOX 8-10 Esophageal Doppler Monitoring Indications and Contraindications
  607. Indications
  608. Contraindications
  609. EMERGING TECHNIQUES AND TECHNOLOGIES
  610. Esophageal Doppler Monitoring
  611. FIGURE 8-24 Esophageal Doppler probe placement.
  612. BOX 8-11 Nurse-Driven Protocol Using Esophageal Doppler Monitoring to Guide Therapy14
  613. FIGURE 8-25 A, CardioQ monitoring system for assessing cardiac output and function via the esophageal Doppler probe. B, Numeric and graphic data provided by the CardioQ device.
  614. TABLE 8-4 Interpretation Guidelines for Esophageal Doppler Monitoring
  615. Pulse Contour Cardiac Output Monitoring
  616. FIGURE 8-26 Schematic of the LiDCO system for assessing cardiac output via the pulse contour analysis method.
  617. FIGURE 8-27 Example of information provided by LiDCO device.
  618. Assessing Effect of Respiratory Variation on Hemodynamic Parameters
  619. Right Atrial Pressure Variation
  620. Systolic Pressure Variation
  621. Arterial Pulse Pressure Variation
  622. Stroke Volume Variation
  623. CASE STUDY
  624. QUESTIONS
  625. SUMMARY
  626. CRITICAL THINKING QUESTIONS
  627. REFERENCES
  628. CHAPTER 9 Ventilatory Assistance
  629. INTRODUCTION
  630. REVIEW OF RESPIRATORY ANATOMY AND PHYSIOLOGY
  631. Upper Airway
  632. Lower Airway
  633. FIGURE 9-1 Anatomy of the respiratory system. The lungs are located in the thoracic cavity. The diaphragm forms the floor of the thoracic cavity and separates it from the abdominal cavity. The internal view of one lung shows air passages.
  634. FIGURE 9-2 The vocal cords/glottis.
  635. Lungs
  636. FIGURE 9-3 Structure and function of the alveolus.
  637. PHYSIOLOGY OF BREATHING
  638. Gas Exchange
  639. FIGURE 9-4 Schematic view of the process of gas exchange. Hgb, Hemoglobin.
  640. Regulation of Breathing
  641. Respiratory Mechanics
  642. Work of Breathing
  643. FIGURE 9-5 Diffusion of oxygen and carbon dioxide at the alveolar-capillary membrane.
  644. Compliance
  645. Resistance
  646. LUNG VOLUMES AND CAPACITIES
  647. TABLE 9-1 Lung Volumes and Capacities
  648. FIGURE 9-6 Lung volumes and capacities.
  649. GERIATRIC CONSIDERATIONS
  650. PHYSIOLOGICAL CHANGES WITH AGING
  651. ASSESSMENT CHANGES
  652. NORMAL FINDINGS BECAUSE OF AGING PROCESS
  653. INCREASED RISK FOR
  654. RESPIRATORY ASSESSMENT
  655. Health History
  656. Physical Examination
  657. Inspection
  658. FIGURE 9-7 Breathing patterns.
  659. Palpation
  660. Percussion
  661. Auscultation
  662. FIGURE 9-8 Systematic method for palpation, percussion, and auscultation of the lungs in anterior (A), posterior (B), and lateral regions (C and D). The techniques should be performed systematically to compare right and left lung fields.
  663. TABLE 9-2 Percussion of the Chest Wall
  664. Breath Sounds
  665. TABLE 9-3 Normal Breath Sounds
  666. Arterial Blood Gas Interpretation
  667. Oxygenation
  668. Partial Pressure of Arterial Oxygen.
  669. Arterial Oxygen Saturation of Hemoglobin.
  670. TABLE 9-4 Adventitious Breath Sounds
  671. TABLE 9-5 Blood Gas Interpretation
  672. Ventilation and Acid-Base Status
  673. pH.
  674. Box 9-1 Signs and Symptoms of Hypoxemia
  675. Integumentary System
  676. Respiratory System
  677. Central Nervous System
  678. Partial Pressure of Arterial Carbon Dioxide.
  679. FIGURE 9-9 Oxyhemoglobin dissociation curve. A PaO2 of 60 mm Hg correlates with an oxygen saturation of 90%. When the PaO2 falls below 60 mm Hg, small changes in PaO2 are reflected in large changes in oxygen saturation. Shifts in the oxyhemoglobin curve. L, Left shift; N, normal; R, right shift.
  680. Sodium Bicarbonate.
  681. Buffer Systems.
  682. Box 9-2 Causes of Common Acid-Base Abnormalities
  683. Respiratory Acidosis: Retention of CO2
  684. Respiratory Alkalosis: Hyperventilation
  685. Metabolic Acidosis
  686. Increased Acids
  687. Loss of Base
  688. Metabolic Alkalosis
  689. Gain of Base
  690. Loss of Metabolic Acids
  691. Base Excess or Base Deficit.
  692. Compensation.
  693. Steps in Arterial Blood Gas Interpretation
  694. Step 1: Look at Each Number Individually and Label It.
  695. FIGURE 9-10 The kidneys and lungs work together to compensate for acid-base imbalances in the respiratory or metabolic systems. HCO3−, Bicarbonate; H2CO3, carbonic acid.
  696. LABORATORY ALERT
  697. Arterial Blood Gas Critical Values*
  698. Step 2: Evaluate Oxygenation.
  699. Step 3: Determine Acid-Base Status.
  700. Step 4: Determine Whether Primary Acid-Base Disorder Is Respiratory or Metabolic.
  701. Step 5: Determine Whether Any Form of Compensatory Response Has Taken Place.
  702. Box 9-3 Examples of Arterial Blood Gases and Compensation
  703. Noninvasive Assessment of Gas Exchange
  704. Assessment of Oxygenation
  705. Pulse Oximetry.
  706. Assessment of Ventilation
  707. End-Tidal Carbon Dioxide Monitoring.
  708. Colorimetric Carbon Dioxide Detector.
  709. FIGURE 9-11 Disposable colorimetric carbon dioxide (CO2) detector for confirming endotracheal tube placement. Detection of CO2 confirms tube placement in the lungs because the only source of CO2 is the alveoli.
  710. OXYGEN ADMINISTRATION
  711. Humidification
  712. Picking the Best Device
  713. Fit and Function
  714. Total Flow
  715. Oxygen Delivery Devices
  716. Nasal Cannula (Variable Performance)
  717. Simple Face Mask (Variable Performance)
  718. Face Masks with Reservoirs (Variable Performance)
  719. Venturi or Air-Entrainment Mask (Fixed Performance)
  720. FIGURE 9-12 Partial rebreathing and nonrebreathing oxygen masks.
  721. FIGURE 9-13 Air-entrainment (Venturi) mask with various jet orifices. Each orifice provides a specific delivered FiO2.
  722. Air Entrainment with Aerosol and Humidity Delivery (Variable or Fixed Performance)
  723. FIGURE 9-14 Devices used to apply high-flow, high-humidity oxygen therapy. A, Aerosol mask. B, Face tent. C, Tracheostomy collar. D, Briggs T-piece.
  724. Manual Resuscitation Bag (Variable Performance)
  725. AIRWAY MANAGEMENT
  726. Positioning
  727. Oral Airways
  728. FIGURE 9-15 Maintaining a patent airway with an oral airway.
  729. Box 9-4 Insertion of Oral Airway
  730. Nasopharyngeal Airways
  731. FIGURE 9-16 The nasopharyngeal airway is used to relieve upper airway obstruction and to facilitate passage of a suction catheter.
  732. Box 9-5 Insertion of Nasal Airway
  733. FIGURE 9-17 Endotracheal tube.
  734. Box 9-6 Oral versus Nasotracheal Intubation
  735. Oral Intubation
  736. Advantages
  737. Disadvantages
  738. Nasotracheal Intubation
  739. Advantages
  740. Disadvantages
  741. Endotracheal Intubation
  742. FIGURE 9-18 Equipment used for endotracheal intubation: A, stylet (disposable); B, endotracheal tube with 10-mL syringe for cuff inflation; C, laryngoscope handle with attached curved blade (left) and straight blade (right); D, water-soluble lubricant; E, colorimetric CO2 detector to check tube placement; F, tape or G, commercial device to secure tube; H, Yankauer disposable pharyngeal suction device; I, Magill forceps (optional). Additional equipment, not shown, includes suction source and stethoscope.
  743. Procedure for Oral Endotracheal Intubation
  744. FIGURE 9-19 Elevating the head with a blanket or folded towels places the patient in the „sniffing position” to facilitate endotracheal intubation.
  745. Procedure for Nasotracheal Intubation
  746. Verification of Endotracheal Tube Placement
  747. Tracheostomy
  748. FIGURE 9-20 Two methods for securing the endotracheal tube: tape (A) and harness device (B). Harness device shown is the SecureEasy Endotracheal Tube Holder. Nonelastic headgear reduces the risk of self-extubation. A soft bite block prevents tube occlusion.
  749. Tracheostomy Tube Designs
  750. Cuffed versus Uncuffed Tracheostomy Tubes.
  751. FIGURE 9-21 General design features of the tracheostomy tube.
  752. Single- versus Double-Cannula Tracheostomy Tubes.
  753. Fenestrated Tracheostomy Tube.
  754. Speaking Tracheostomy Valves.
  755. Endotracheal Suctioning
  756. Box 9-7 Key Points for Endotracheal Suctioning
  757. FIGURE 9-22 Closed tracheal suction device.
  758. EVIDENCE-BASED PRACTICE
  759. PROBLEM
  760. QUESTION
  761. REFERENCE
  762. EVIDENCE
  763. IMPLICATIONS FOR NURSING
  764. MECHANICAL VENTILATION
  765. Indications
  766. Positive-Pressure Ventilation
  767. Ventilator Settings
  768. Fraction of Inspired Oxygen
  769. FIGURE 9-23 Concept of positive-pressure ventilation.
  770. Tidal Volume
  771. FIGURE 9-24 Examples of mechanical ventilators, their control panels and graphic interface unit (GIU). A, Servo ventilator 300A control panel. B, Puritan Bennett 840 ventilator GIU.
  772. Exhaled Tidal Volume.
  773. Respiratory Rate
  774. Inspiratory-to-Expiratory Ratio
  775. Inverse Inspiratory-to-Expiratory Ratio
  776. Positive End-Expiratory Pressure
  777. FIGURE 9-25 Effect of application of positive end-expiratory pressure (PEEP) on the alveoli.
  778. Auto-PEEP.
  779. Sensitivity
  780. Sigh
  781. Patient Data
  782. Peak Inspiratory Pressure
  783. Total Respiratory Rate
  784. Modes of Mechanical Ventilation
  785. Volume-Controlled Ventilation
  786. Assist/Control Ventilation.
  787. FIGURE 9-26 Waveforms of volume-controlled ventilator modes. A, Volume assist control (A/C) ventilation. The patient may trigger additional breaths above the set rate. The ventilator delivers the same volume for ventilator-triggered and patient-triggered (assisted) breaths. B, Synchronized intermittent mandatory ventilation (SIMV). Both spontaneous and mandatory breaths are graphed. Mandatory breaths receive the set tidal volume (VT). VT of spontaneous breaths depends on work patient is capable of generating, lung compliance, and airway resistance.
  788. Synchronized Intermittent Mandatory Ventilation.
  789. Pressure-Controlled Ventilation
  790. Continuous Positive Airway Pressure.
  791. Pressure Support.
  792. FIGURE 9-27 Continuous positive airway pressure (CPAP) is a spontaneous breathing mode. Positive pressure at end expiration splints alveoli and supports oxygenation. I, Inspiration; E, Expiration.
  793. FIGURE 9-28 Pressure support ventilation requires the patient to trigger each breath, which is then supported by pressure on inspiration. Patient may vary amount of time in inspiration, respiratory rate, and tidal volume (VT).
  794. Pressure Assist/Control.
  795. FIGURE 9-29 Synchronized intermittent mandatory ventilation (SIMV) with pressure support (PS). SIMV breaths receive set tidal volume (VT). Pressure support is applied to the spontaneous, patient-triggered breaths.
  796. FIGURE 9-30 Pressure assist/control ventilation. Patient can trigger additional breaths above the set rate. Patient- and ventilator-triggered breaths receive the same inspiratory pressure.
  797. Pressure-Controlled Inverse-Ratio Ventilation.
  798. FIGURE 9-31 Airway pressure—release ventilation. See text below for description.
  799. Airway Pressure—Release Ventilation.
  800. Noninvasive Positive-Pressure Ventilation
  801. FIGURE 9-32 Masks used for noninvasive positive-pressure ventilation. A, Nasal. B, Oronasal. C, Total face mask.
  802. FIGURE 9-33 Noninvasive positive-pressure ventilation (NIPPV) may be administered through a mask with the BiPAP Vision ventilator. This ventilator is capable of operating in four modes: pressure support (PS); spontaneous/timed (S/T) mode, which is pressure support with back-up pressure control; timed (T), which is pressure control; and continuous positive airway pressure (CPAP). (Courtesy of Respironics, Murrysville, PA.)
  803. Advanced Methods and Modes of Mechanical Ventilation
  804. Respiratory Monitoring During Mechanical Ventilation
  805. Alarm Systems
  806. Volume Alarms.
  807. Pressure Alarms.
  808. Apnea Alarm.
  809. TABLE 9-6 Management of Common Ventilator Alarms
  810. Complications of Mechanical Ventilation
  811. Airway Problems
  812. Intubation of Right Mainstem Bronchus.
  813. CLINICAL ALERT
  814. Implementation of the Ventilator Bundle
  815. Endotracheal Tube Out of Position.
  816. Unplanned Extubation.
  817. Laryngeal and Tracheal Injury.
  818. Damage to the Oral or Nasal Mucosa.
  819. FIGURE 9-34 Monitoring endotracheal tube cuff pressures.
  820. Box 9-8 Strategies for Unplanned or Self-Extubation
  821. Pulmonary System
  822. Trauma.
  823. Oxygen Toxicity.
  824. Respiratory Acidosis or Alkalosis.
  825. Infection.
  826. Cardiovascular System
  827. Gastrointestinal System
  828. Psychosocial Complications
  829. NURSING CARE
  830. Communication
  831. NURSING CARE PLAN for the Mechanically Ventilated Patient21
  832. NURSING DIAGNOSIS
  833. PATIENT OUTCOMES
  834. NURSING DIAGNOSIS
  835. PATIENT OUTCOMES
  836. NURSING DIAGNOSIS
  837. PATIENT OUTCOMES
  838. NURSING DIAGNOSIS
  839. PATIENT OUTCOMES
  840. NURSING DIAGNOSIS
  841. PATIENT OUTCOMES
  842. NURSING DIAGNOSIS
  843. PATIENT OUTCOME
  844. NURSING DIAGNOSIS
  845. PATIENT OUTCOME
  846. Medications
  847. WEANING PATIENTS FROM MECHANICAL VENTILATION
  848. Methods for Weaning
  849. Synchronized Intermittent Mandatory Ventilation
  850. Pressure Support
  851. T-Piece
  852. Continuous Positive Airway Pressure
  853. Approach to Weaning Using Best Evidence
  854. Assessment for Readiness to Wean (Wean Screen)
  855. Box 9-9 Evidence-Based Guidelines for Weaning from Mechanical Ventilation39,40
  856. Weaning Process (Weaning Trial)
  857. Box 9-10 Assessment Parameters Indicating Readiness to Wean
  858. Underlying Cause for Mechanical Ventilation Resolved
  859. Hemodynamic Stability; Adequate Cardiac Output
  860. Adequate Respiratory Muscle Strength
  861. Adequate Oxygenation Without a High FiO2 and/or a High PEEP
  862. Absence of Factors that Impair Weaning
  863. Box 9-11 Criteria for Discontinuing Weaning
  864. Respiratory
  865. Cardiovascular
  866. Neurological
  867. Extubation
  868. CASE STUDY
  869. QUESTIONS
  870. SUMMARY
  871. CRITICAL THINKING QUESTIONS
  872. REFERENCES
  873. CHAPTER 10 Code Management
  874. INTRODUCTION
  875. ROLES OF CAREGIVERS IN CODE MANAGEMENT
  876. Code Team
  877. Leader of the Code
  878. TABLE 10-1 Roles and Responsibilities of Code Team Members
  879. Code Nurses
  880. Primary Nurse.
  881. Second Nurse.
  882. Nursing Supervisor.
  883. Anesthesiologist or Nurse Anesthetist
  884. Respiratory Therapist
  885. Pharmacist or Pharmacy Technician
  886. Electrocardiogram Technician
  887. Chaplain
  888. Other Personnel
  889. EQUIPMENT USED IN CODES
  890. FIGURE 10-1 A typical crash cart.
  891. TABLE 10-2 Typical Contents of a Crash Cart
  892. RESUSCITATION EFFORTS
  893. TABLE 10-3 Flow of Events during a Code
  894. Basic Life Support
  895. Airway
  896. Breathing
  897. BOX 10-1 Steps in Basic Cardiac Life Support
  898. Airway
  899. Breathing
  900. Circulation
  901. Defibrillation
  902. FIGURE 10-2 Head-tilt/chin-lift technique for opening the airway. A, Obstruction by the tongue. B, Head-tilt/chin-lift maneuver lifts tongue relieving airway obstruction.
  903. FIGURE 10-3 Mouth-to-mask ventilation.
  904. FIGURE 10-4 Rescue breathing with bag-valve device.
  905. Circulation
  906. Advanced Cardiac Life Support
  907. Primary Survey
  908. Secondary Survey
  909. Airway
  910. Breathing
  911. FIGURE 10-5 Ventilation with a bag-valve device connected to endotracheal tube.
  912. Circulation
  913. FIGURE 10-6 End-tidal carbon dioxide detector connected to an endotracheal tube. Exhaled carbon dioxide reacts with the device to create a color change indicating correct endotracheal tube placement.
  914. Differential Diagnosis
  915. Recognition and Treatment of Dysrhythmias
  916. Ventricular Fibrillation and Pulseless Ventricular Tachycardia
  917. Critical Actions
  918. Pulseless Electrical Activity and Asystole
  919. Critical Actions
  920. Symptomatic Bradycardia
  921. Critical Actions
  922. BOX 10-2 Signs and Symptoms of Low Cardiac Output Associated with Bradycardia
  923. Unstable Tachycardia
  924. Critical Actions
  925. Electrical Therapy
  926. Defibrillation
  927. Definition.
  928. FIGURE 10-7 Defibrillator.
  929. Procedure.
  930. FIGURE 10-8 Paddle placement for defibrillation.
  931. FIGURE 10-9 Anteroposterior placement of adhesive electrode pads for defibrillation or transcutaneous pacing.
  932. BOX 10-3 Procedure for External Defibrillation
  933. Automated External Defibrillation
  934. Definition.
  935. Indications.
  936. Procedure.
  937. Cardioversion
  938. Definition.
  939. FIGURE 10-10 Automatic external defibrillator.
  940. BOX 10-4 Procedure for Automated External Defibrillator Operation
  941. Procedure.
  942. FIGURE 10-11 Approximate location of the vulnerable period.
  943. BOX 10-5 Procedure for Synchronous Cardioversion
  944. Special Situations
  945. FIGURE 10-12 Monitor/defibrillator demonstrating marked R waves for cardioversion.
  946. Transcutaneous Cardiac Pacing
  947. Definition.
  948. Procedure.
  949. FIGURE 10-13 Transcutaneous pacemaker-defibrillator.
  950. FIGURE 10-14 Electrical capture of transcutaneous pacemaker. Note the pacemaker spikes followed by a wide QRS complex and a tall T wave.
  951. BOX 10-6 Procedure for Transcutaneous Pacemaker
  952. PHARMACOLOGICAL INTERVENTION DURING A CODE
  953. Oxygen
  954. Epinephrine (Adrenalin)
  955. BOX 10-7 Effects of Adrenergic Receptor Stimulation
  956. Alpha
  957. Beta1
  958. Beta2
  959. Vasopressin
  960. Atropine
  961. PHARMACOLOGY TABLE 10-4 Drugs Frequently Used in Code Management
  962. Amiodarone (Cordarone)
  963. Lidocaine (Xylocaine)
  964. Procainamide (Pronestyl)
  965. Adenosine (Adenocard)
  966. Magnesium
  967. Sodium Bicarbonate
  968. FIGURE 10-15 Atrioventricular block after intravenous administration of adenosine.
  969. FIGURE 10-16 Torsades de pointes. The QRS complex seems to spiral around the isoelectric line.
  970. Dopamine (Intropin)
  971. Calcium Chloride
  972. SPECIAL PROBLEMS DURING A CODE
  973. GERIATRIC CONSIDERATIONS
  974. Tension Pneumothorax
  975. Pericardial Tamponade
  976. DOCUMENTATION OF CODE EVENTS
  977. FIGURE 10-17 Tension pneumothorax. On inspiration, air enters the pleural space. On expiration, air is unable to escape the pleural space. Pressure increases, causing the lung on the affected side to collapse and the trachea to shift to the opposite side.
  978. CARE OF THE PATIENT AFTER RESUSCITATION
  979. FIGURE 10-18 Sample of a code record used for documenting activities during a code.
  980. LABORATORY ALERTS
  981. Therapeutic Hypothermia After Cardiac Arrest
  982. EVIDENCE-BASED PRACTICE
  983. Therapeutic Hypothermia
  984. PROBLEM
  985. QUESTION
  986. REFERENCES
  987. EVIDENCE
  988. IMPLICATIONS FOR NURSING
  989. Family Presence during Resuscitation
  990. EVIDENCE-BASED PRACTICE
  991. Code Management
  992. PROBLEM
  993. QUESTION
  994. REFERENCES
  995. EVIDENCE
  996. NURSING IMPLICATIONS
  997. Rapid Response Teams
  998. SUMMARY
  999. CRITICAL THINKING QUESTIONS
  1000. REFERENCES
  1001. Part III Nursing Care during Critical Illness
  1002. CHAPTER 11 Shock, Sepsis, and Multiple Organ Dysfunction Syndrome
  1003. INTRODUCTION
  1004. REVIEW OF ANATOMY AND PHYSIOLOGY
  1005. FIGURE 11-1 Microcirculation. AV, Arteriovenous.
  1006. Pathophysiology
  1007. TABLE 11-1 Classification of Shock
  1008. Stages of Shock
  1009. Stage I: Initiation
  1010. Stage II: Compensatory Stage
  1011. Neural Compensation.
  1012. Endocrine Compensation.
  1013. FIGURE 11-2 Impairment of cellular metabolism by shock. ATP, Adenosine triphosphate; Na, sodium; NH 4, ammonia; K, potassium.
  1014. TABLE 11-2 Stages of Shock
  1015. FIGURE 11-3 The renin-angiotensin-aldosterone system.
  1016. Chemical Compensation.
  1017. Stage III: Progressive Stage
  1018. Stage IV: Refractory Stage
  1019. Systemic Inflammatory Response Syndrome (SIRS)
  1020. Effects of Aging
  1021. ASSESSMENT
  1022. Clinical Presentation
  1023. Central Nervous System
  1024. Cardiovascular System
  1025. CLINICAL ALERT
  1026. TABLE 11-3 Hemodynamic Alterations in Shock States
  1027. Respiratory System
  1028. Renal System
  1029. Gastrointestinal System
  1030. Hematological System
  1031. Integumentary System
  1032. Laboratory Studies
  1033. LABORATORY ALERTS
  1034. MANAGEMENT
  1035. Maintenance of Circulating Blood Volume and Adequate Hemoglobin Level
  1036. Intravenous Access
  1037. Fluid Challenge
  1038. Types of Fluids
  1039. FIGURE 11-4 Fluid challenge algorithm. CVP, Central venous pressure; PAOP, pulmonary artery occlusion pressure.
  1040. EVIDENCE-BASED PRACTICE
  1041. PROBLEM
  1042. QUESTION
  1043. REFERENCES
  1044. EVIDENCE
  1045. IMPLICATIONS FOR NURSING
  1046. Maintenance of Arterial Oxygen Saturation and Ventilation
  1047. Pharmacological Support
  1048. Cardiac Output
  1049. FIGURE 11-5 Therapeutic manipulation of cardiac output and myocardial oxygen consumption. ACE, Angiotensin converting enzyme; ARB, angiotensin receptor blocker; CI, cardiac index; CO, cardiac output; CVP, central venous pressure; IABP, intra-aortic balloon pump; LR, lactated Ringer’s; LV, left ventricle; LVSWI, left ventricular stroke work index; NS, normal (0.9%) saline; NTG, nitroglycerin; PAOP, pulmonary artery occlusive pressure; PDE, phosphodiesterase; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricle; RVSWI, right ventricular stroke work index; SVR, systemic vascular resistance.
  1050. PHARMACOLOGY TABLE 11-4 Medications Commonly Used in Shock
  1051. Preload
  1052. Afterload
  1053. Contractility
  1054. Other Medications
  1055. Maintenance of Body Temperature
  1056. Nutritional Support
  1057. Maintenance of Skin Integrity
  1058. Psychological Support
  1059. NURSING DIAGNOSIS
  1060. NURSING CARE PLAN for the Patient in Shock
  1061. NURSING DIAGNOSIS
  1062. PATIENT OUTCOMES
  1063. Adequate tissue perfusion
  1064. SPECIFIC CLASSIFICATIONS OF SHOCK
  1065. Hypovolemic Shock
  1066. TABLE 11-5 Summary of Classifications of Shock
  1067. FIGURE 11-6 Hypovolemic shock.
  1068. TABLE 11-6 Severity of Hemorrhagic Shock
  1069. Cardiogenic Shock
  1070. FIGURE 11-7 Cardiogenic shock. ADH, Antidiuretic hormone; SVR, systemic vascular resistance.
  1071. FIGURE 11-8 Cycle of cardiogenic shock.
  1072. FIGURE 11-9 Intraaortic balloon pump. The balloon is deflated during systole (A) and inflated during diastole (B).
  1073. Obstructive Shock
  1074. FIGURE 11-10 Obstructive shock.
  1075. Distributive Shock
  1076. Neurogenic Shock
  1077. FIGURE 11-11 Neurogenic shock. SVR, Systemic vascular resistance.
  1078. Anaphylactic Shock
  1079. FIGURE 11-12 Anaphylactic shock. IgE, Immunoglobulin E; SVR, systemic vascular resistance.
  1080. Septic Shock
  1081. TABLE 11-7 Clinical Condition, Diagnostic Criteria, and Management in the Continuum of Sepsis
  1082. FIGURE 11-13 Sepsis and septic shock pathophysiology.
  1083. TABLE 11-8 Stages of Septic Shock
  1084. MULTIPLE ORGAN DYSFUNCTION SYNDROME
  1085. FIGURE 11-14 Pathogenesis of multiple organ dysfunction syndrome. MODS, Multiple organ dysfunction syndrome; GI, gastrointestinal; PAF, platelet activating factor; WBCs, white blood cells; MDF, myocardial depressant factor.
  1086. PATIENT OUTCOMES
  1087. TABLE 11-9 Multiple Organ Dysfunction Syndrome
  1088. CASE STUDY
  1089. QUESTIONS
  1090. SUMMARY
  1091. CRITICAL THINKING QUESTIONS
  1092. REFERENCES
  1093. CHAPTER 12 Cardiovascular Alterations
  1094. INTRODUCTION
  1095. NORMAL STRUCTURE AND FUNCTION OF THE HEART
  1096. FIGURE 12-1 The heart lies in the mediastinum, between the lungs. Its apex rests on the diaphragm. The heart is covered by the pericardium. The inset shows the layers of the heart muscle and the pericardium.
  1097. FIGURE 12-2 Structure of the heart and course of blood flow through the heart chambers.
  1098. Autonomic Control
  1099. Coronary Circulation
  1100. FIGURE 12-3 A, The atrioventricular (AV) valves in the open position and the semilunar (SL) valves in the closed position. B, The AV valves in the closed position and the SL valves in the open position.
  1101. FIGURE 12-4 Autonomic control of circulation. AV, Atrioventricular; Pvv, pulmonary venules; Raa, renal arterioles; SA, sinoatrial.
  1102. BOX 12-1 Coronary Artery Distribution
  1103. Right Coronary Artery
  1104. Left Anterior Descending Artery
  1105. Circumflex Artery
  1106. Other Cardiac Functions
  1107. Heart Sounds
  1108. FIGURE 12-5 The coronary vessels.
  1109. FIGURE 12-6 Chest areas from which each valve sound is best heard.
  1110. TABLE 12-1 Grading of Heart Murmurs
  1111. Heart Murmur
  1112. CORONARY ARTERY DISEASE
  1113. Pathophysiology
  1114. Assessment
  1115. Patient Assessment
  1116. FIGURE 12-7 Schematic of atherosclerotic plaque. 1. Accumulation of lipoprotein particles in the intima. 2. Oxidative stress. 3. Induction of the cytokines and movement into the intima. 4. Blood monocytes encounter stimuli that augment their expression of scavenger receptors. 5. Scavenger receptors mediate the uptake of modified lipoprotein particles and promote the development of foam cells. Cytokines and superoxide anion (O2−). 6. Smooth muscle cells divide and migrate into the intima from the media. 7. Smooth muscle cells promote extracellular atherosclerotic plaque growth. Fatty streaks evolve into fatty lesions. 8. Calcification can occur and fibrosis continues.
  1117. BOX 12-2 Risk Factors for Coronary Artery Disease
  1118. Gender
  1119. Heredity
  1120. Age
  1121. Smoking
  1122. Blood Cholesterol
  1123. High Blood Pressure
  1124. Physical Inactivity
  1125. Overweight and Obesity
  1126. Diabetes
  1127. BOX 12-3 Questioning of Activities for Stress Reduction
  1128. CLINICAL ALERT
  1129. TABLE 12-2 Major Systems Assessment
  1130. Diagnostic Studies
  1131. 12-Lead Electrocardiography.
  1132. Holter Monitor.
  1133. Exercise Tolerance Test (ETT) or Stress Test.
  1134. Chest X-ray.
  1135. Echocardiography.
  1136. Transesophageal Echocardiography.
  1137. Diagnostic Heart Scans.
  1138. Technetium-99m Stannous Pyrophosphate.
  1139. Thallium-201.
  1140. Multigated Blood Pool Study.
  1141. Nitroglycerin MUGA.
  1142. Sestamibi Exercise Testing and Scan.
  1143. Single Photon Emission Computed Tomography.
  1144. Cardiac Catheterization and Arteriography.
  1145. Magnetic Resonance Imaging.
  1146. FIGURE 12-8 FemoStop in correct position.
  1147. BOX 12-4 Nursing Care after Cardiac Catheterization and Arteriography
  1148. Electrophysiology Study.
  1149. Laboratory Diagnostics
  1150. Serum Electrolytes.
  1151. Serum Enzymes.
  1152. TABLE 12-3 ECG Changes Associated with Electrolyte Imbalances
  1153. Nursing Diagnoses
  1154. Interventions
  1155. Nursing Interventions
  1156. Medical Management
  1157. Medications to Reduce Serum Lipid Levels.
  1158. PHARMACOLOGY TABLE 12-4 Medications for Lowering Cholesterol and Triglycerides
  1159. LABORATORY ALERT
  1160. Medications to Prevent Platelet Adhesion and Aggregation.
  1161. Patient Outcomes
  1162. ANGINA
  1163. Pathophysiology
  1164. Types of Angina
  1165. BOX 12-5 Factors That Influence Oxygen Demand and Supply
  1166. Increased Oxygen Demand
  1167. Reduced Oxygen Supply
  1168. Assessment
  1169. CLINICAL ALERT
  1170. Diagnostic Studies
  1171. Nursing Diagnoses
  1172. Interventions
  1173. Nursing Interventions
  1174. Medical Interventions
  1175. PHARMACOLOGY TABLE 12-5 Drugs for Acute Coronary Syndromes
  1176. BOX 12-6 Instructions Regarding Nitroglycerin
  1177. Outcomes
  1178. ACUTE MYOCARDIAL INFARCTION
  1179. Pathophysiology
  1180. EVIDENCE-BASED PRACTICE
  1181. PROBLEM
  1182. QUESTION
  1183. REFERENCE
  1184. EVIDENCE
  1185. IMPLICATIONS FOR NURSING
  1186. FIGURE 12-9 Electrocardiographic alterations associated with the three zones of myocardial infarction.
  1187. Assessment
  1188. Patient Assessment
  1189. Diagnosis
  1190. Nursing Diagnoses
  1191. Complications
  1192. Medical Interventions
  1193. TABLE 12-6 Myocardial Infarction by Site, Electrocardiographic Changes, and Complications
  1194. Pain Relief.
  1195. Oxygen.
  1196. Antidysrhythmics.
  1197. Prevention of Platelet Aggregation.
  1198. Thrombolytic Therapy.
  1199. TABLE 12-7 Criteria for Diagnosis of Acute Coronary Syndrome
  1200. Percutaneous Coronary Intervention.
  1201. NURSING CARE PLAN for the Patient with Acute Myocardial Infarction
  1202. NURSING DIAGNOSIS
  1203. PATIENT OUTCOMES
  1204. NURSING DIAGNOSIS
  1205. PATIENT OUTCOMES
  1206. NURSING DIAGNOSIS
  1207. PATIENT OUTCOMES
  1208. NURSING DIAGNOSIS
  1209. PATIENT OUTCOMES
  1210. PHARMACOLOGY TABLE 12-8 Thrombolytics
  1211. Facilitated Percutaneous Coronary Intervention.
  1212. Medications.
  1213. Nitrates.
  1214. Beta-Blockers.
  1215. Angiotensin-Converting Enzyme Inhibitors.
  1216. Outcomes
  1217. INTERVENTIONAL CARDIOLOGY
  1218. Percutaneous Transluminal Coronary Angioplasty
  1219. FIGURE 12-10 Coronary angioplasty procedure. A-D, Order of procedure.
  1220. Complications
  1221. Intracoronary Stent
  1222. FIGURE 12-11 Radiographs of patients with triple-vessel disease with images before (A and B) and after (C and D) angioplasty.
  1223. SURGICAL REVASCULARIZATION
  1224. Coronary Artery Bypass Graft
  1225. FIGURE 12-12 Coronary artery bypass graft surgery. Saphenous vein is harvested from the leg using either a traditional long incision or less-invasive videoscopic harvesting (A). The vein is then anastomosed to the coronary artery (B).
  1226. Minimally Invasive Coronary Artery Surgery
  1227. Transmyocardial Revascularization
  1228. BOX 12-7 Key Points for Maintaining Chest and Mediastinal Tubes
  1229. Definitions
  1230. Baseline Assessment
  1231. Maintaining the Chest Drainage System
  1232. Assisting with Removal
  1233. Autotransfusion
  1234. Management after Cardiac Surgery
  1235. Complications of Cardiac Surgery
  1236. CARDIAC DYSRHYTHMIAS
  1237. BOX 12-8 Nursing Interventions after Cardiac Surgery
  1238. Radiofrequency Catheter Ablation
  1239. PHARMACOLOGY TABLE 12-9 Medications Used to Treat Dysrhythmias
  1240. Permanent Pacemakers
  1241. Implantable Cardioverter-Defibrillator
  1242. TABLE 12-10 Modified Generic Code for Pacemakers
  1243. BOX 12-9 Indications for an Implantable Cardioverter-Defibrillator
  1244. BOX 12-10 Patient and Family Teaching for an Implantable Cardioverter-Defibrillator
  1245. Preprocedural Teaching
  1246. Postprocedural Teaching
  1247. HEART FAILURE
  1248. Pathophysiology
  1249. TABLE 12-11 Heart Failure Stages and Descriptions
  1250. BOX 12-11 Causes of Heart Failure
  1251. Left Heart Systolic Failure
  1252. Left Heart Diastolic Failure
  1253. Right Heart Systolic Failure
  1254. Right Heart Diastolic Failure
  1255. BOX 12-12 Signs and Symptoms of Heart Failure
  1256. Left-Sided Heart Failure: Poor Pump
  1257. Right Sided Hearty Failure: Excess Volume
  1258. Assessment
  1259. Nursing Diagnoses
  1260. Interventions
  1261. NURSING CARE PLAN for the Patient with Heart Failure
  1262. NURSING DIAGNOSIS
  1263. PATIENT OUTCOMES
  1264. NURSING DIAGNOSIS
  1265. PATIENT OUTCOMES
  1266. NURSING DIAGNOSIS
  1267. PATIENT OUTCOMES
  1268. NURSING DIAGNOSIS
  1269. PATIENT OUTCOMES
  1270. NURSING DIAGNOSIS
  1271. PATIENT OUTCOMES
  1272. NURSING DIAGNOSIS
  1273. PATIENT OUTCOME
  1274. PHARMACOLOGY TABLE 12-13 Specific Medications for Heart Failure
  1275. TABLE 12-12 Medication Subsets for Heart Failure
  1276. Complications
  1277. Pulmonary Edema
  1278. TRANSPLANTATION Cardiac
  1279. INDICATIONS
  1280. CRITERIA FOR TRANSPLANT RECIPIENT
  1281. CRITERIA FOR DONOR
  1282. PATIENT MANAGEMENT
  1283. COMPLICATIONS
  1284. PREVENTING REJECTION
  1285. REFERENCES
  1286. Cardiogenic Shock
  1287. PERICARDIAL DISEASE
  1288. Pericarditis
  1289. ENDOCARDITIS
  1290. VASCULAR ALTERATIONS
  1291. FIGURE 12-13 Anatomy of the aorta and its major branches.
  1292. Aortic Aneurysms
  1293. FIGURE 12-14 The four types of aneurysms.
  1294. Aortic Dissection
  1295. Nursing Assessment
  1296. Diagnostic Studies
  1297. GENETICS
  1298. MARFAN SYNDROME
  1299. REFERENCES
  1300. Treatment
  1301. FIGURE 12-15 Surgical repair of an abdominal aortic aneurysm. The aneuysmal sac is incised (A). The synthetic graft is inserted (B), and the native aortic wall is sutured over the synthetic graft (C).
  1302. BOX 12-13 Nursing Interventions after Aortic Surgery
  1303. CASE STUDY
  1304. QUESTIONS
  1305. SUMMARY
  1306. GERIATRIC CONSIDERATIONS
  1307. MEDICATIONS
  1308. PROCEDURES
  1309. SURGERY
  1310. POSTOPERATIVE
  1311. FAMILY
  1312. REHABILITATION
  1313. CRITICAL THINKING QUESTIONS
  1314. REFERENCES
  1315. CHAPTER 13 Nervous System Alterations
  1316. INTRODUCTION
  1317. ANATOMY AND PHYSIOLOGY OF THE NERVOUS SYSTEM
  1318. Cells of the Nervous System
  1319. FIGURE 13-1 A neuron, the basic element of the nervous system.
  1320. Transmission of Nerve Impulses
  1321. Synapses
  1322. Neurotransmitters
  1323. Cerebral Circulation
  1324. TABLE 13-1 Common Neurotransmitters and Their Actions
  1325. Brain Metabolism
  1326. FIGURE 13-2 Arteries at the base of the brain. The arteries that compose the circle of Willis are the two anterior cerebral arteries, joined to each other by the anterior communicating two short segments of the internal carotids, off of which the posterior communicating arteries connect to the posterior cerebral arteries.
  1327. Brain Barrier System
  1328. Ventricular System and Cerebrospinal Fluid
  1329. FUNCTIONAL AND STRUCTURAL DIVISIONS OF THE CENTRAL NERVOUS SYSTEM
  1330. Meninges
  1331. FIGURE 13-3 Cerebrospinal fluid (CSF) circulation. Arrows represent the route of CSF. CSF is produced in the ventricles and returns to the venous circulation in the superior sagittal sinus.
  1332. Brain (Encephalon)
  1333. Cerebrum
  1334. FIGURE 13-4 Frontal section of the skull and brain showing the relationships of the meninges.
  1335. FIGURE 13-5 Major divisions of the central nervous system.
  1336. FIGURE 13-6 The structures of the brain (midsagittal section).
  1337. FIGURE 13-7 Cerebral hemispheres.
  1338. Diencephalon
  1339. Brainstem
  1340. Cerebellum
  1341. Specialized Systems within the Central Nervous System
  1342. Spinal Cord
  1343. FIGURE 13-8 Each of the 31 pairs of spinal nerves exit the spinal cavity from the vertebrae. The names of the vertebrae are listed on the left, and the corresponding spinal nerves are listed on the right.
  1344. Plexuses
  1345. Peripheral Nervous System
  1346. Autonomic Nervous System
  1347. FIGURE 13-9 Dermatome distribution of spinal nerves. A, Anterior view. B, Posterior view. C, Side view.
  1348. Effects of Aging
  1349. TABLE 13-2 The Cranial Nerves and Assessment in the Critically Ill Patient
  1350. GERIATRIC CONSIDERATIONS
  1351. Assessment
  1352. CLINICAL ALERT
  1353. Neurological Assessment
  1354. Mental Status.
  1355. FIGURE 13-10 The Glasgow Coma Scale is based on eye opening, movement, and verbal responses. Each response is given a number, and the three scores are summed. Scores range from 3 to 15.
  1356. Language Skills.
  1357. Memory.
  1358. Cranial Nerve Functioning.
  1359. Motor Status.
  1360. Spontaneous Movement.
  1361. Muscle Strength.
  1362. Muscle Tone.
  1363. Deep Tendon Reflexes.
  1364. Babinski’s Reflex.
  1365. Coordination.
  1366. Abnormal Posture.
  1367. Sensory Assessment.
  1368. FIGURE 13-11 Deep tendon reflexes. A, Biceps. B, Triceps. C, Brachioradialis. D, Patellar. E, Achilles.
  1369. Respiratory Assessment.
  1370. Hourly Assessment.
  1371. INCREASED INTRACRANIAL PRESSURE
  1372. FIGURE 13-12 Babinski’s reflex. A, Light pressure is applied with a hard object to the lateral surface of the sole, starting at the heel and going over the ball of the foot ending beneath the great toe. B, Normal response is flexion of all toes. C, Positive Babinski’s response is dorsiflexion of the great toe and fanning of the other toes.
  1373. FIGURE 13-13 Abnormal motor responses. A, Flexion posturing. B, Extensor posturing. C, Flexion posturing on right side and extensor posturing on left side.
  1374. TABLE 13-3 Spinal Nerve Innervation of Major Muscle Groups
  1375. Pathophysiology
  1376. TABLE 13-4 Respiratory Patterns in Neurological Disorders
  1377. FIGURE 13-14 Intracranial pressure–volume curve. Between points A and B, intracranial compliance is present. Intracranial pressure (ICP) is normal, and increases in intracranial volume are tolerated without large increases in ICP. As compliance is lost, small increases in volume result in large and dangerous increases in ICP (points C and D).
  1378. FIGURE 13-15 Pathophysiology flow diagram for increased intracranial pressure.
  1379. TABLE 13-5 Components of the Hourly Neurological Assessment for Patients with Increased Intracranial Pressure, Head Injury, or Acute Stroke
  1380. TABLE 13-6 Herniation Syndromes
  1381. Causes of Increased Intracranial Pressure
  1382. Increased Brain Volume
  1383. BOX 13-1 Risk Factors for Increased Intracranial Pressure
  1384. Increased Brain Volume
  1385. Increased Cerebral Blood Flow
  1386. Increased Cerebrospinal Fluid
  1387. Increased Cerebral Blood Volume
  1388. Loss of Autoregulation.
  1389. Decreased Cerebral Oxygenation.
  1390. Increased Metabolic Demands.
  1391. Obstructed Venous Outflow.
  1392. FIGURE 13-16 Herniation syndromes. A, Normal intracranial structures. B, Supratentorial herniation syndromes. C, Cerebellar tonsil herniation.
  1393. CLINICAL ALERT
  1394. Optimal Positioning
  1395. Increased Cerebrospinal Fluid
  1396. Assessment
  1397. Monitoring Techniques
  1398. Intracranial Pressure Monitoring.
  1399. FIGURE 13-17 Intracranial pressure monitoring sites.
  1400. Intracranial Pressure Waveform Monitoring.
  1401. FIGURE 13-18 Intracranial pressure (ICP) waveforms. A, Normal ICP waveform. B, Abnormal waveform.
  1402. TABLE 13-7 Intracranial Pressure Monitoring Devices3
  1403. Ventriculostomy.
  1404. Hemodynamic Monitoring.
  1405. Cerebral Oxygenation Monitoring.
  1406. FIGURE 13-19 Becker external drainage and monitoring system. (Courtesy of Medtronic, Minneapolis, MN.)
  1407. Respiratory Monitoring.
  1408. Bedside Electroencephalographic Monitoring.
  1409. Diagnostic Testing
  1410. Nursing Diagnoses
  1411. Management
  1412. Medical and Nursing Interventions (Nonsurgical)
  1413. Nursing Actions to Manage Intracranial Pressure.
  1414. NURSING CARE PLAN for the Patient with Traumatic Brain Injury, Increased Intracranial Pressure, or Acute Stroke
  1415. NURSING DIAGNOSIS
  1416. PATIENT OUTCOMES
  1417. Optimal cerebral perfusion
  1418. NURSING DIAGNOSIS
  1419. PATIENT OUTCOMES
  1420. Improved cerebral tissue perfusion
  1421. NURSING DIAGNOSIS
  1422. Optimal gas exchange
  1423. Optimal gas exchange
  1424. NURSING DIAGNOSIS
  1425. PATIENT OUTCOMES
  1426. Optimal fluid balance
  1427. NURSING DIAGNOSIS
  1428. Optimal nutrition
  1429. Optimal nutrition
  1430. NURSING DIAGNOSES
  1431. PATIENT OUTCOMES
  1432. Free of infection
  1433. NURSING DIAGNOSIS
  1434. PATIENT OUTCOMES
  1435. Optimal thought processes
  1436. NURSING DIAGNOSIS
  1437. PATIENT OUTCOME
  1438. Family demonstrates effective adaptation to the situation
  1439. Medical Management.
  1440. Adequate Oxygenation.
  1441. Management of Carbon Dioxide.
  1442. Diuretics.
  1443. Optimal Fluid Administration.
  1444. Blood Pressure Management.
  1445. Reducing Metabolic Demands.
  1446. Temperature Control.
  1447. Sedation.
  1448. PHARMACOLOGY TABLE 13-8 Frequently Used Drugs in Nervous System Alterations
  1449. EVIDENCE-BASED PRACTICE
  1450. PROBLEM
  1451. QUESTION
  1452. REFERENCE
  1453. EVIDENCE
  1454. IMPLICATIONS FOR NURSING
  1455. Seizure Prophylaxis.
  1456. Neuromuscular Blockade and Barbiturate Therapy.
  1457. Surgical Interventions
  1458. Psychosocial Support
  1459. TRAUMATIC BRAIN INJURY
  1460. Pathophysiology
  1461. FIGURE 13-20 Pathophysiology flow diagram for traumatic brain injury. CSF, Cerebrospinal fluid; Ca++, calcium; ICP, intracranial pressure.
  1462. TABLE 13-9 Types of Traumatic Injury with Associated Signs and Symptoms
  1463. Scalp Lacerations
  1464. FIGURE 13-21 Coup and contrecoup head injury after blunt trauma. A, Coup injury: impact against object. a, Site of impact and direct trauma to the brain. b, Shearing of the subdural veins. c, Trauma to the base of the brain. B, Contrecoup injury: impact within skull. a, Site of impact from brain hitting opposite side of skull. b, Shearing forces throughout the brain. These injuries occur in one continuous motion—the head strikes the wall (coup), then rebounds (contrecoup).
  1465. Skull Fractures
  1466. Linear Skull Fracture.
  1467. FIGURE 13-22 Skull fractures. A, Linear; open, depressed; basilar and comminuted fractures. B, View of base of skull with fractures.
  1468. Depressed Skull Fracture.
  1469. FIGURE 13-23 A, Raccoon eyes, rhinorrhea. B, Battle’s sign with otorrhea. C, Halo or ring sign.
  1470. Comminuted Skull Fracture.
  1471. Brain Injury
  1472. Primary Brain Injury.
  1473. Concussion.
  1474. Contusion.
  1475. Diffuse Axonal Injury.
  1476. Penetrating Injury.
  1477. FIGURE 13-24 Types of hematomas. A, Subdural (takes on contour of brain). B, Epidural. C, Intracerebral.
  1478. Hematoma.
  1479. Epidural Hematoma.
  1480. Subdural Hematoma.
  1481. Intracerebral Hematoma.
  1482. Secondary Brain Injury.
  1483. Assessment
  1484. Nursing Diagnoses
  1485. Management
  1486. Medical (Nonsurgical) Interventions
  1487. Surgical Interventions
  1488. ACUTE STROKE
  1489. GENETICS
  1490. APOLIPOPROTEIN E AND COGNITIVE RECOVERY AFTER BRAIN INJURY
  1491. REFERENCES
  1492. Pathophysiology
  1493. Ischemic Stroke
  1494. Large Artery Atherosclerosis.
  1495. FIGURE 13-25 Proximal occlusion of left middle cerebral artery with infarction. Ischemic penumbra represents regional blood flow at about 25 mL/100 g/min. Ischemic penumbra is the area where acute therapies for stroke are targeted.
  1496. Cardioembolic Stroke.
  1497. Lacunar Stroke.
  1498. FIGURE 13-26 Common arterial and cardiac abnormalities causing ischemic stroke.
  1499. Cryptogenic Stroke.
  1500. Hemorrhagic Stroke
  1501. Intraparenchymal Hemorrhage.
  1502. Ruptured Cerebral Aneurysm with Subarachnoid Hemorrhage.
  1503. Arteriovenous Malformation.
  1504. Assessment
  1505. BOX 13-2 Signs and Symptoms of Stroke
  1506. TABLE 13-10 National Institutes of Health Stroke Scale
  1507. Diagnostic Tests
  1508. Management
  1509. Nursing Diagnoses
  1510. Ischemic Stroke
  1511. Thrombolytic Candidates.
  1512. BOX 13-3 Diagnostic Testing for Stroke
  1513. Initial Diagnostic Testing
  1514. Additional Diagnostic Testing1
  1515. Nonthrombolytic Candidates.
  1516. BOX 13-4 Administration of Tissue Plasminogen Activator for Acute Ischemic Stroke
  1517. Inclusion Criteria
  1518. Exclusion Criteria
  1519. Administration
  1520. Other Ischemic Events
  1521. Transient Ischemic Attacks.
  1522. Hemorrhagic Stroke
  1523. Intraparenchymal Stroke.
  1524. Subarachnoid Hemorrhage
  1525. Arteriovenous Malformation
  1526. Postoperative Neurosurgical Care
  1527. SEIZURES AND STATUS EPILEPTICUS
  1528. TABLE 13-11 Classification of Seizures
  1529. Pathophysiology of Status Epilepticus
  1530. Assessment
  1531. Diagnostic Tests
  1532. Management
  1533. Nursing Diagnoses
  1534. Nursing and Medical Interventions
  1535. CENTRAL NERVOUS SYSTEM INFECTIONS
  1536. Bacterial Meningitis
  1537. Pathophysiology
  1538. BOX 13-5 Causes of Meningitis
  1539. Bacterial
  1540. Viruses
  1541. Fungal
  1542. Assessment
  1543. Diagnostic Tests
  1544. Management
  1545. Nursing Diagnoses.
  1546. TABLE 13-12 Manifestations of Cranial Nerve Inflammation in Bacterial Meningitis
  1547. Nursing and Medical Management.
  1548. SPINAL CORD INJURY
  1549. Pathophysiology
  1550. Assessment
  1551. Airway and Respiratory Assessment
  1552. Neurological Assessment
  1553. Hemodynamic Assessment
  1554. FIGURE 13-27 Pathophysiology flow diagram for spinal cord injury. ANS, Autonomic nervous system; K+, potassium; Na+, sodium; Ca2+, calcium; O2, oxygen; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in arterial blood.
  1555. Bowel and Bladder Function
  1556. FIGURE 13-28 Common spinal cord syndromes.
  1557. Skin Assessment
  1558. TABLE 13-13 Components of the Hourly Neurological Assessment for Patients with Spinal Cord Injury*
  1559. Psychological Assessment
  1560. Diagnostic Studies
  1561. BOX 13-6 Autonomic Dysreflexia
  1562. Medical Emergency; Can Result in Stroke, Seizures, or Other Complications
  1563. Triggered by a Variety of Stimuli
  1564. Common Signs and Symptoms
  1565. Treatment
  1566. Management
  1567. Nursing Interventions
  1568. NURSING CARE PLAN for the Patient with Spinal Cord Injury
  1569. NURSING DIAGNOSIS
  1570. PATIENT OUTCOMES Risk for injury minimized
  1571. NURSING DIAGNOSIS
  1572. PATIENT OUTCOMES Adequate gas exchange
  1573. NURSING DIAGNOSIS
  1574. PATIENT OUTCOME
  1575. Within 24-48 hours, airway clear
  1576. NURSING DIAGNOSIS
  1577. PATIENT OUTCOME
  1578. NURSING DIAGNOSIS
  1579. PATIENT OUTCOMES Adequate CO
  1580. NURSING DIAGNOSIS
  1581. PATIENT OUTCOMES Adequate nutrition
  1582. NURSING DIAGNOSIS
  1583. PATIENT OUTCOME
  1584. NURSING DIAGNOSIS
  1585. PATIENT OUTCOMES
  1586. Free of infection
  1587. NURSING DIAGNOSIS
  1588. PATIENT OUTCOME
  1589. NURSING DIAGNOSIS
  1590. PATIENT OUTCOME
  1591. NURSING DIAGNOSIS
  1592. PATIENT OUTCOMES
  1593. Reduced fear and anxiety
  1594. NURSING DIAGNOSIS
  1595. PATIENT OUTCOME
  1596. Nursing and Medical Interventions
  1597. FIGURE 13-29 Halo vest.
  1598. Surgical Intervention
  1599. CASE STUDY
  1600. QUESTIONS
  1601. SUMMARY
  1602. CRITICAL THINKING QUESTIONS
  1603. REFERENCES
  1604. CHAPTER 14 Acute Respiratory Failure
  1605. INTRODUCTION
  1606. ACUTE RESPIRATORY FAILURE
  1607. Definition
  1608. Pathophysiology
  1609. Failure of Oxygenation
  1610. Hypoventilation.
  1611. Intrapulmonary Shunting.
  1612. FIGURE 14-1 Pulmonary causes of hypoxemia. A, Normal alveolar-capillary unit. B, Hypoventilation causes an increased PaCO2 and decreased PaO2. C, Shunt. D, Ventilation-perfusion mismatch resulting from pulmonary embolus. E, Diffusion defect due to increased interstitial fluid.
  1613. Ventilation-Perfusion Mismatch.
  1614. Diffusion Defects.
  1615. Low Cardiac Output.
  1616. Low Hemoglobin Level.
  1617. Tissue Hypoxia.
  1618. Failure of Ventilation
  1619. Hypoventilation.
  1620. Ventilation-Perfusion Mismatch.
  1621. Assessment
  1622. Effects of Aging
  1623. GERIATRIC CONSIDERATIONS
  1624. Interventions
  1625. CLINICAL ALERT
  1626. Nursing Diagnoses
  1627. RESPIRATORY FAILURE IN ACUTE RESPIRATORY DISTRESS SYNDROME
  1628. Definition
  1629. NURSING CARE PLAN for a Patient with Acute Respiratory Failure*
  1630. NURSING DIAGNOSIS
  1631. PATIENT OUTCOMEs
  1632. NURSING DIAGNOSIS
  1633. PATIENT OUTCOMES
  1634. NURSING DIAGNOSIS
  1635. PATIENT OUTCOMES
  1636. Absence of infection
  1637. NURSING DIAGNOSIS
  1638. PATIENT OUTCOMES
  1639. Anxiety decreased or absent
  1640. NURSING DIAGNOSIS
  1641. PATIENT OUTCOMES
  1642. NURSING DIAGNOSIS
  1643. PATIENT OUTCOMES
  1644. Family integrity maintained
  1645. Etiology
  1646. TABLE 14-1 Mechanical Ventilation Protocol for Acute Respiratory Distress Syndrome (NHLBI, NIH)
  1647. BOX 14-1 Possible Causes for Acute Respiratory Distress Syndrome
  1648. Direct Causes
  1649. Indirect Causes
  1650. Pathophysiology
  1651. Assessment
  1652. FIGURE 14-2 Pathogenesis of acute respiratory distress syndrome (ARDS). TNF, Tumor necrosis factor; IL-1, interleukin-1; PAF, platelet-activating factor; RBCs, red blood cells.
  1653. Interventions
  1654. Oxygenation
  1655. EVIDENCE-BASED PRACTICE
  1656. PROBLEM
  1657. QUESTION
  1658. REFERENCE
  1659. EVIDENCE
  1660. IMPLICATIONS FOR NURSING
  1661. Sedation/Comfort
  1662. Prone Positioning
  1663. Fluid and Electrolytes
  1664. Nutrition
  1665. Pharmacological Treatment
  1666. Psychosocial Support
  1667. ACUTE RESPIRATORY FAILURE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  1668. Pathophysiology
  1669. TABLE 14-2 Pathological and Physiological Changes in Chronic Obstructive Pulmonary Disease
  1670. Assessment
  1671. CLINICAL ALERT
  1672. Interventions
  1673. Oxygen
  1674. BOX 14-2 Treatment of Stable Chronic Obstructive Pulmonary Disease
  1675. Bronchodilator Therapy
  1676. TABLE 14-3 Bronchodilators
  1677. Corticosteroids
  1678. Antibiotics
  1679. Ventilatory Assistance
  1680. ACUTE RESPIRATORY FAILURE IN ASTHMA
  1681. Pathophysiology
  1682. Assessment
  1683. FIGURE 14-3 Airway obstruction caused by asthma. A, Normal lung. B, Bronchial asthma: thick mucus, mucosal edema, and smooth muscle spasm causing obstruction of small airways.
  1684. Interventions
  1685. BOX 14-3 Asthma Triggers
  1686. Inhalant Allergens
  1687. Occupational Exposure
  1688. Irritants
  1689. Other Factors Influencing Asthma Severity
  1690. CLINICAL ALERT
  1691. TABLE 14-4 Emergency Treatment of Severe Asthma
  1692. ACUTE RESPIRATORY FAILURE RESULTING FROM VENTILATOR-ASSOCIATED PNEUMONIA
  1693. Definition and Etiology
  1694. FIGURE 14-4 Role of airway management in the pathogenesis of ventilator-associated pneumonia.
  1695. Pathophysiology
  1696. Assessment
  1697. TABLE 14-5 Modified Clinical Pulmonary Infection Score
  1698. Interventions
  1699. Prevention
  1700. Hand Hygiene and Universal Precautions.
  1701. Respiratory Equipment.
  1702. BOX 14-4 Prevention of Ventilator-Associated Pneumonia
  1703. Patient Position and Mobility.
  1704. Oral Care.
  1705. Gastric Tubes, Nutrition, and Peptic Ulcer Prophylaxis.
  1706. BOX 14-5 Example of a Comprehensive Oral Care Protocol
  1707. Interventions
  1708. Equipment
  1709. Sedation Interruption and Daily Assessment of Readiness to Extubate.
  1710. Treatment
  1711. ACUTE RESPIRATORY FAILURE RESULTING FROM PULMONARY EMBOLISM
  1712. Definition/Classification
  1713. Etiology
  1714. Pathophysiology
  1715. BOX 14-6 Risk Factors for Venous Thromboembolism
  1716. Venous Stasis
  1717. Vessel Wall Injury
  1718. Hypercoagulability
  1719. Assessment
  1720. Diagnosis
  1721. Arterial Blood Gases.
  1722. Electrocardiogram.
  1723. Chest X-ray.
  1724. D-dimer Assay.
  1725. Ventilation-Perfusion Scan.
  1726. Duplex Ultrasonography.
  1727. Echocardiogram.
  1728. High-Resolution Multidetector Computed Tomography Angiography.
  1729. Magnetic Resonance Imaging.
  1730. Pulmonary Angiogram.
  1731. Prevention
  1732. Treatment
  1733. BOX 14-7 Nursing Measures to Prevent Venous Thromboembolism
  1734. GENETICS
  1735. CYSTIC FIBROSIS: A HERITABLE DISORDER WITH PULMONARY AND GASTROINTESTINAL COMPLICATIONS
  1736. REFERENCES
  1737. TRANSPLANTATION Lung
  1738. INTRODUCTION
  1739. CRITERIA FOR TRANSPLANT RECIPIENTS
  1740. CRITERIA FOR DONORS
  1741. PATIENT MANAGEMENT
  1742. COMPLICATIONS
  1743. PREVENTING REJECTION
  1744. REFERENCES
  1745. ACUTE RESPIRATORY FAILURE IN ADULT PATIENTS WITH CYSTIC FIBROSIS
  1746. Definition
  1747. Etiology
  1748. Interventions
  1749. CASE STUDY
  1750. QUESTIONS
  1751. SUMMARY
  1752. CRITICAL THINKING QUESTIONS
  1753. REFERENCES
  1754. CHAPTER 15 Acute Renal Failure
  1755. INTRODUCTION
  1756. REVIEW OF ANATOMY AND PHYSIOLOGY
  1757. FIGURE 15-1 Anatomy of the nephron, the functional unit of the kidney.
  1758. BOX 15-1 Functions of the Kidney
  1759. Regulation of Fluid and Electrolytes and Excretion of Waste Products
  1760. Regulation of Acid-Base Balance
  1761. FIGURE 15-2 Average pressures involved in filtration from the glomerular capillaries.
  1762. Regulation of Blood Pressure
  1763. FIGURE 15-3 Renin-angiotensin mechanism.
  1764. Effects of Aging
  1765. PATHOPHYSIOLOGY OF ACUTE RENAL FAILURE
  1766. Definition
  1767. Etiology
  1768. Prerenal Causes of Acute Renal Failure
  1769. Postrenal Causes of Acute Renal Failure
  1770. Intrarenal Causes of Acute Renal Failure
  1771. BOX 15-2 Prerenal Causes of Acute Renal Failure
  1772. Volume Depletion
  1773. Vasodilation
  1774. Impaired Cardiac Performance
  1775. Miscellaneous
  1776. BOX 15-3 Postrenal Causes of Acute Renal Failure
  1777. Acute Tubular Necrosis.
  1778. FIGURE 15-4 Schematic of loss of glomerular filtration seen in ischemic and nephrotoxic acute tubular necrosis.
  1779. BOX 15-4 Intrarenal Causes of Acute Renal Failure
  1780. Glomerular, Vascular, or Hematological Problems
  1781. Tubular Problem (Acute Tubular Necrosis or Acute Interstitial Nephritis)
  1782. Contrast-Induced Nephropathy.
  1783. EVIDENCE-BASED PRACTICE
  1784. Acute Renal Failure
  1785. PROBLEM
  1786. QUESTION
  1787. REFERENCE
  1788. EVIDENCE
  1789. IMPLICATIONS FOR NURSING
  1790. Course of Acute Renal Failure
  1791. Initiation (Onset) Phase.
  1792. Maintenance (Oliguric/Anuric) Phase.
  1793. Recovery (Diuretic) Phase.
  1794. ASSESSMENT
  1795. Patient History
  1796. BOX 15-5 Common Nephrotoxic Medications
  1797. Vital Signs
  1798. Physical Assessment
  1799. TABLE 15-1 Systemic Manifestations of Acute Renal Failure
  1800. Evaluation of Laboratory Values
  1801. CLINICAL ALERT
  1802. Serum Creatinine
  1803. TABLE 15-2 Laboratory Findings Useful in Differentiating Causes of Acute Renal Failure
  1804. Diagnostic Procedures
  1805. GERIATRIC CONSIDERATIONS
  1806. Management of Acute Renal Failure
  1807. NURSING DIAGNOSES
  1808. NURSING INTERVENTIONS
  1809. TABLE 15-3 Invasive Diagnostic Procedures for Assessing the Renal System
  1810. NURSING CARE PLAN for the Patient with Acute Renal Failure
  1811. NURSING DIAGNOSIS
  1812. PATIENT OUTCOMES
  1813. Stable fluid balance
  1814. NURSING DIAGNOSIS
  1815. PATIENT OUTCOMES
  1816. Absence of infection
  1817. NURSING DIAGNOSIS
  1818. PATIENT OUTCOMES
  1819. Adequate nutritional and caloric intake
  1820. NURSING DIAGNOSIS
  1821. PATIENT OUTCOME Anxiety levels reduced
  1822. NURSING DIAGNOSIS
  1823. PATIENT OUTCOME
  1824. CLINICAL ALERT
  1825. Fluid Volume Overload
  1826. MEDICAL MANAGEMENT OF ACUTE RENAL FAILURE
  1827. Prerenal Causes
  1828. Postrenal Causes
  1829. Intrarenal Causes: Acute Tubular Necrosis
  1830. Pharmacological Management
  1831. Diuretics.
  1832. BOX 15-6 Measures to Prevent Acute Renal Failure
  1833. Avoid Nephrotoxins
  1834. Optimize Volume Status Before Surgery or Invasive Procedures
  1835. Reduce Incidence of Nosocomial Infections
  1836. Implement Tight Glycemic Control in the Critically Ill
  1837. Aggressively Investigate and Treat Sepsis
  1838. Dopamine.
  1839. Acetylcysteine.
  1840. Fenoldopam.
  1841. Theophylline.
  1842. Miscellaneous Agents.
  1843. Epoetin Alfa (Epogen).
  1844. Pharmacological Management Considerations.
  1845. Dietary Management
  1846. BOX 15-7 Common Drugs Removed by Hemodialysis*
  1847. Management of Fluid, Electrolyte, and Acid-Base Imbalances
  1848. Fluid Imbalance.
  1849. Electrolyte Imbalance.
  1850. LABORATORY ALERT
  1851. Acute Renal Failure
  1852. FIGURE 15-5 Electrocardiographic (ECG) changes seen in hyperkalemia.
  1853. Acid-Base Imbalance.
  1854. PHARMACOLOGY TABLE 15-4 Medications to Treat Hyperkalemia
  1855. BOX 15-8 Metabolic Acidosis in Acute Renal Failure
  1856. Etiology
  1857. Signs and Symptoms
  1858. Renal Replacement Therapy
  1859. Definition.
  1860. Indications for Dialysis.
  1861. Principles and Mechanisms.
  1862. Vascular Access.
  1863. FIGURE 15-6 Central venous catheter used for hemodialysis.
  1864. FIGURE 15-7 Hemodialysis access devices.
  1865. Nursing Care of Arteriovenous Fistula or Graft.
  1866. Nursing Care of Percutaneous Catheters.
  1867. Hemodialysis.
  1868. Complications.
  1869. Nursing Care of the Patient.
  1870. BOX 15-9 Complications of Dialysis
  1871. Continuous Renal Replacement Therapy.
  1872. TABLE 15-5 Continuous Renal Replacement Therapies
  1873. Indications.
  1874. Principles.
  1875. Complications.
  1876. Nursing Care.
  1877. Peritoneal Dialysis.
  1878. FIGURE 15-8 Schematic of A, continuous venovenous hemofiltration (CVVH) and B, continuous venovenous hemofiltration dialysis (CVVHD).
  1879. Indications.
  1880. Complications.
  1881. FIGURE 15-9 Prismaflex continuous renal replacement therapy system.
  1882. Contraindications.
  1883. TRANSPLANTATION Renal
  1884. INDICATIONS
  1885. CRITERIA FOR TRANSPLANT RECIPIENT
  1886. CRITERIA FOR DONORS
  1887. PATIENT MANAGEMENT
  1888. COMPLICATIONS
  1889. PREVENTING REJECTION
  1890. REFERENCES
  1891. OUTCOMES
  1892. CASE STUDY
  1893. QUESTIONS
  1894. SUMMARY
  1895. CRITICAL THINKING QUESTIONS
  1896. REFERENCES
  1897. CHAPTER 16 Hematological and Immune Disorders
  1898. INTRODUCTION
  1899. REVIEW OF ANATOMY AND PHYSIOLOGY
  1900. Hematopoiesis
  1901. Effects of Aging
  1902. Components and Characteristics of Blood
  1903. TABLE 16-1 Hematology-Immunology Key Terms
  1904. Hematopoietic Cells
  1905. Erythrocytes
  1906. FIGURE 16-1 Hematopoietic stem cell and lineage.
  1907. FIGURE 16-2 Hematopoietic organs and their function.
  1908. GERIATRIC CONSIDERATIONS
  1909. Platelets
  1910. TABLE 16-2 Characteristics of Blood
  1911. Leukocytes
  1912. Granular Leukocytes
  1913. Neutrophils.
  1914. TABLE 16-3 Overview of Leukocytes
  1915. Eosinophils.
  1916. Basophils.
  1917. Nongranular Leukocytes (Agranulocytes)
  1918. Monocytes.
  1919. Lymphocytes.
  1920. Immune Anatomy
  1921. Immune Physiology
  1922. Nonspecific Defenses
  1923. Epithelial Surfaces.
  1924. Inflammation and Phagocytosis.
  1925. Other Nonspecific Defenses.
  1926. Specific Defenses
  1927. Humoral Immunity.
  1928. Cell-Mediated Immunity.
  1929. TABLE 16-4 Immunoglobulins
  1930. Hemostasis
  1931. FIGURE 16-3 Coagulation physiology.
  1932. Coagulation Pathway
  1933. Coagulation Antagonists and Clot Lysis
  1934. FIGURE 16-4 Coagulation cascade.
  1935. NURSING ASSESSMENT OF HEMATOLOGICAL AND IMMUNOLOGICAL FUNCTION
  1936. TRANSPLANTATION Hematopoietic Stem Cell Transplantation
  1937. INDICATIONS
  1938. CATEGORIES
  1939. TISSUE TYPING
  1940. COMPLICATIONS
  1941. REFERENCES
  1942. Past Medical History
  1943. Evaluation of Patient Complaints and Physical Examination
  1944. FIGURE 16-5 Fibrinolysis.
  1945. Diagnostic Tests
  1946. BOX 16-1 Conditions that may Indicate Hematological and Immunological Problems*
  1947. SELECTED ERYTHROCYTE DISORDERS
  1948. TABLE 16-5 Physical Assessment for Hemotological and Immune Disorders
  1949. Anemia
  1950. Pathophysiology
  1951. TABLE 16-6 Functions and Normal Values of Blood Cells
  1952. Assessment and Clinical Manifestations
  1953. TABLE 16-7 Coagulation Profile Studies
  1954. Nursing Diagnoses
  1955. TABLE 16-8 Anemias
  1956. Medical Interventions
  1957. Nursing Interventions
  1958. WHITE BLOOD CELL AND IMMUNE DISORDERS
  1959. The Immunocompromised Patient
  1960. Pathophysiology
  1961. Assessment and Clinical Manifestations
  1962. Nursing Diagnoses
  1963. Medical Interventions
  1964. TABLE 16-9 Risk Factors for Infections in the Immunocompromised Patient
  1965. CLINICAL ALERT
  1966. Infection in Immunocompromised Patients
  1967. Nursing Interventions
  1968. Neutropenia
  1969. Pathophysiology
  1970. Assessment and Clinical Manifestations
  1971. NURSING CARE PLAN for the Immunocompromised Patient
  1972. NURSING DIAGNOSIS
  1973. PATIENT OUTCOMES
  1974. Patient will remain free of infection
  1975. NURSING DIAGNOSIS
  1976. PATIENT OUTCOMES
  1977. Skin and mucous membranes intact
  1978. NURSING DIAGNOSIS
  1979. PATIENT OUTCOMES
  1980. Optimal nutritional status maintained
  1981. EVIDENCE-BASED PRACTICE
  1982. PROBLEM
  1983. QUESTION
  1984. REFERENCE
  1985. EVIDENCE
  1986. IMPLICATIONS FOR NURSING
  1987. Nursing Diagnoses
  1988. Medical Interventions
  1989. BOX 16-2 Causes of Neutropenia
  1990. Malnutrition
  1991. Health States
  1992. Medications
  1993. Nursing Interventions
  1994. Malignant White Blood Cell Disorders: Leukemia, Lymphoma, and Multiple Myeloma
  1995. Pathophysiology
  1996. Assessment and Clinical Manifestations
  1997. TABLE 16-10 Malignant White Blood Cell Disorders
  1998. Nursing Diagnoses
  1999. Medical Interventions
  2000. Nursing Interventions
  2001. SELECTED IMMUNOLOGICAL DISORDERS
  2002. Primary Immunodeficiency
  2003. Secondary Immunodeficiency
  2004. Acquired Immunodeficiency Syndrome
  2005. Pathophysiology.
  2006. Assessment and Clinical Manifestations.
  2007. FIGURE 16-6 Human immunodeficiency virus (HIV) pathophysiology. CMV, Cytomegalovirus; CNS, central nervous system; ELISA, enzyme-linked immunosorbent assay; TB, tuberculosis.
  2008. Nursing Diagnoses.
  2009. Medical Interventions.
  2010. Nursing Interventions.
  2011. BLEEDING DISORDERS
  2012. The Bleeding Patient
  2013. Pathophysiology
  2014. Assessment and Clinical Manifestations
  2015. Nursing Diagnoses
  2016. Medical Interventions
  2017. NURSING CARE PLAN for the Patient with a Bleeding Disorder
  2018. NURSING DIAGNOSIS
  2019. PATIENT OUTCOMES
  2020. Adequate perfusion maintained and damage to vital organs prevented
  2021. NURSING DIAGNOSIS
  2022. PATIENT OUTCOMES Free of bleeding and normovolemic
  2023. Nursing Interventions
  2024. TABLE 16-11 Summary of Blood Products and Administration
  2025. Thrombocytopenia
  2026. Pathophysiology
  2027. Assessment and Clinical Manifestations
  2028. Box 16-3 Causes of Thrombocytopenia
  2029. Bone Marrow Suppression
  2030. Interference with Platelet Production (Other than Nonspecific Marrow Suppression)
  2031. Platelet Destruction Outside the Bone Marrow
  2032. Immune Response Against Platelets
  2033. Interference with Platelet Function
  2034. Nursing Diagnoses
  2035. Medical Interventions
  2036. Box 16-4 Heparin-Induced Thrombocytopenia11,15,22
  2037. Definition
  2038. Risks
  2039. Complications
  2040. Diagnosis
  2041. Treatment
  2042. CLINICAL ALERT
  2043. Bleeding Disorders
  2044. Nursing Interventions
  2045. Disseminated Intravascular Coagulation
  2046. Pathophysiology
  2047. Assessment and Clinical Manifestations
  2048. FIGURE 16-7 Pathophysiology of disseminated intravascular coagulopathy.
  2049. Nursing Diagnoses
  2050. Medical Interventions
  2051. TABLE 16-12 Causes of Disseminated Intravascular Coagulation
  2052. GENETICS
  2053. FACTOR V LEIDEN: AN INHERITED CLOTTING DISORDER
  2054. REFERENCES
  2055. LABORATORY FINDINGS
  2056. Disseminated Intravascular Coagulation
  2057. Nursing Interventions
  2058. CASE STUDY
  2059. QUESTIONS
  2060. SUMMARY
  2061. CRITICAL THINKING QUESTIONS
  2062. REFERENCES
  2063. CHAPTER 17 Gastrointestinal Alterations
  2064. INTRODUCTION
  2065. REVIEW OF ANATOMY AND PHYSIOLOGY
  2066. Gastrointestinal Tract
  2067. Gut Wall
  2068. Mucosa.
  2069. Gastric Mucosal Barrier.
  2070. FIGURE 17-1 The gastrointestinal system.
  2071. Submucosa.
  2072. Oropharyngeal Cavity
  2073. Mouth.
  2074. BOX 17-1 Swallowing Stages
  2075. Oral: Voluntary
  2076. Pharyngeal: Involuntary
  2077. Esophageal: Involuntary
  2078. Salivary Glands.
  2079. Pharynx.
  2080. Esophagus
  2081. FIGURE 17-2 The stomach.
  2082. Stomach
  2083. TABLE 17-1 Gastric Secretions
  2084. Small Intestine
  2085. TABLE 17-2 Electrolyte and Acid-Base Disturbances Associated with the Gastrointestinal Tract
  2086. TABLE 17-3 Pancreatic Enzymes and Their Actions
  2087. Large Intestine
  2088. Accessory Organs
  2089. Pancreas
  2090. FIGURE 17-3 The intestinal system.
  2091. FIGURE 17-4 The pancreas.
  2092. Liver
  2093. FIGURE 17-5 The normal liver lobule.
  2094. Vascular Functions
  2095. Blood Storage.
  2096. Blood Filtration.
  2097. BOX 17-2 Functions of the Liver
  2098. Vascular Functions
  2099. Secretory Functions
  2100. Metabolic Functions
  2101. Storage Functions
  2102. Secretory Functions
  2103. Bile Production.
  2104. Bilirubin Metabolism.
  2105. Metabolic Functions
  2106. Carbohydrate Metabolism.
  2107. Fat Metabolism.
  2108. Protein Metabolism.
  2109. Production and Removal of Blood Clotting Factors.
  2110. Detoxification.
  2111. Storage, Synthesis, and Transport of Vitamins and Minerals.
  2112. Gallbladder
  2113. Neural Innervation of the Gastrointestinal System
  2114. Hormonal Control of the Gastrointestinal System
  2115. Blood Supply of the Gastrointestinal System
  2116. Geriatric Concerns
  2117. TABLE 17-4 Actions of Gastrointestinal Hormones
  2118. GENERAL ASSESSMENT OF THE GASTROINTESTINAL SYSTEM
  2119. History
  2120. Inspection
  2121. GERIATRIC CONSIDERATIONS
  2122. Skin Color and Texture
  2123. Symmetry and Contour of Abdomen
  2124. Masses and Pulsations
  2125. Peristalsis and Movement
  2126. Auscultation
  2127. BOX 17-3 Causes of Increased and Decreased Bowel Sounds
  2128. Causes of Decreased Bowel Sounds
  2129. Causes of Increased Bowel Sounds
  2130. Percussion
  2131. Palpation
  2132. ACUTE GASTROINTESTINAL BLEEDING
  2133. Pathophysiology
  2134. Peptic Ulcer Disease
  2135. FIGURE 17-6 Duodenal ulcer. A, Deep ulceration in the duodenal wall extending as a crater through the entire mucosa and into the muscle layers. B, Duodenal ulcer.
  2136. BOX 17-4 Causes of Gastrointestinal Bleeding
  2137. Causes of Upper Gastrointestinal Bleeding
  2138. Causes of Lower Gastrointestinal Bleeding8
  2139. Stress Ulcers
  2140. BOX 17-6 Contributing Factors to Ulcer Formation8
  2141. BOX 17-5 Risk Factors for Peptic Ulcer Disease
  2142. Mallory-Weiss Tear
  2143. TABLE 17-5 Selected Studies of Gastrointestinal Function14
  2144. TABLE 17-6 Characteristics of Gastric and Duodenal Ulcers
  2145. Esophageal Varices
  2146. FIGURE 17-7 The liver and collateral circulation.
  2147. Assessment
  2148. Clinical Presentation
  2149. CLINICAL ALERT
  2150. Clinical Signs and Symptoms of Upper Gastrointestinal Bleeding9
  2151. Nursing Assessment
  2152. FIGURE 17-8 Pathophysiology flow diagram of acute upper gastrointestinal (GI) bleeding. BP, Blood pressure.
  2153. Medical Assessment
  2154. Laboratory Studies.
  2155. LABORATORY ALERTS
  2156. Upper Gastrointestinal Bleeding5
  2157. Complete Blood Count
  2158. Serum Electrolyte Panel
  2159. Hematology Profile
  2160. Arterial Blood Gases
  2161. Gastric Aspirate for pH and Guaiac
  2162. Endoscopy and Barium Study.
  2163. Nursing Diagnoses
  2164. Collaborative Management: Nursing and Medical Considerations
  2165. NURSING CARE PLAN for the Patient with Acute Gastrointestinal Bleeding
  2166. NURSING DIAGNOSIS
  2167. PATIENT OUTCOMES
  2168. Adequate circulating blood volume
  2169. NURSING DIAGNOSIS
  2170. PATIENT OUTCOMES
  2171. Adequate tissue perfusion
  2172. NURSING DIAGNOSIS
  2173. PATIENT OUTCOMES
  2174. BOX 17-7 Management of Upper Gastrointestinal Bleeding
  2175. Hemodynamic Stabilization
  2176. Definitive and Supportive Therapies
  2177. Hemodynamic Stabilization
  2178. Gastric Lavage
  2179. Pharmacological Therapy
  2180. Antibiotics.
  2181. Endoscopic Therapy
  2182. PHARMACOLOGY TABLE 17-7 Pharmacological Treatments to Decrease Gastric Acid Secretion and/or Reduce Acid Effects on Gastric Mucosa10
  2183. Surgical Therapy
  2184. GENETICS
  2185. Cytochrome P450 Enzymes and the Patient’s Response to Drugs
  2186. REFERENCES
  2187. FIGURE 17-9 Billroth I and II procedures.
  2188. Nursing Diagnoses
  2189. Recognition of Potential Complications
  2190. CLINICAL ALERT
  2191. Acute Gastric Perforation9
  2192. Treatment of Variceal Bleeding
  2193. Somatostatin or Octreotide
  2194. Vasopressin
  2195. Endoscopic Procedures
  2196. 17-8 Vasopressin (Pitressin) Therapy10
  2197. Mechanism of Action
  2198. Dose
  2199. Side Effects
  2200. Nursing Considerations
  2201. Transjugular Intrahepatic Portosystemic Shunt
  2202. FIGURE 17-10 Sengstaken-Blakemore tube.
  2203. Esophagogastric Tamponade
  2204. Surgical Interventions
  2205. FIGURE 17-11 Types of portacaval shunts. A, Normal portal circulation. B, End-to-side shunt. C, Side-to-side shunt.
  2206. Patient Outcomes
  2207. ACUTE PANCREATITIS
  2208. Pathophysiology
  2209. BOX 17-9 Systemic Complications of Acute Pancreatitis
  2210. Pulmonary
  2211. Cardiovascular
  2212. Hematological
  2213. Gastrointestinal
  2214. Renal
  2215. Metabolic
  2216. Assessment
  2217. History and Physical Examination
  2218. BOX 17-10 Causes of Acute Pancreatitis
  2219. LABORATORY ALERTS
  2220. Pancreatitis5
  2221. CLINICAL ALERT
  2222. Signs and Symptoms of Acute Pancreatitis9
  2223. Diagnostic Tests
  2224. BOX 17-11 Other Conditions Associated with Increased Serum Amylase Levels
  2225. Predicting the Severity of Acute Pancreatitis
  2226. BOX 17-12 Ranson Criteria for Predicting Severity of Acute Pancreatitis*
  2227. At Admission or on Diagnosis
  2228. During Initial 48 Hours
  2229. Nursing Diagnoses
  2230. Medical and Nursing Interventions
  2231. Fluid Replacement
  2232. EVIDENCE-BASED PRACTICE
  2233. PROBLEM
  2234. QUESTION
  2235. REFERENCES
  2236. EVIDENCE
  2237. IMPLICATIONS FOR NURSING
  2238. NURSING CARE PLAN
  2239. for the Patient with Acute Pancreatitis
  2240. NURSING DIAGNOSIS
  2241. PATIENT OUTCOMES
  2242. Adequate fluid volume
  2243. NURSING DIAGNOSIS
  2244. PATIENT OUTCOMES
  2245. NURSING DIAGNOSIS
  2246. PATIENT OUTCOMES
  2247. Adequate nutrition
  2248. NURSING DIAGNOSIS
  2249. PATIENT OUTCOMES
  2250. Adequate gas exchange
  2251. NURSING DIAGNOSIS
  2252. PATIENT OUTCOMES
  2253. Electrolyte Replacement
  2254. Nutrition Support
  2255. Comfort Management
  2256. Pharmacological Intervention
  2257. Treatment of Systemic Complications
  2258. Surgical Therapy
  2259. Patient Outcomes
  2260. HEPATIC FAILURE
  2261. Pathophysiology
  2262. Hepatitis
  2263. Assessment.
  2264. Nursing Diagnoses.
  2265. Medical and Nursing Interventions.
  2266. BOX 17-13 Modes of Transmission for Hepatitis
  2267. CLINICAL ALERT
  2268. Signs and Symptoms of Fulminant Hepatic Failure9
  2269. TABLE 17-8 Characteristics of Hepatitis
  2270. TRANSPLANTATION Liver
  2271. INDICATIONS
  2272. CRITERIA FOR TRANSPLANT RECIPIENTS
  2273. CRITERIA FOR DONORS
  2274. PATIENT MANAGEMENT
  2275. COMPLICATIONS
  2276. PREVENTING REJECTION
  2277. REFERENCES
  2278. BOX 17-14 Common Hepatotoxic Drugs
  2279. Analgesics
  2280. Anesthetics
  2281. Anticonvulsants
  2282. Antidepressants
  2283. Antimicrobial Agents
  2284. Antipsychotic Drugs
  2285. Cardiovascular Drugs
  2286. Hormonal Agents
  2287. Sedatives
  2288. Others
  2289. Cirrhosis
  2290. Fatty Liver
  2291. Assessment of Hepatic Failure
  2292. Presenting Clinical Signs
  2293. Portal Hypertension.
  2294. TABLE 17-9 Characteristics of Types of Cirrhosis
  2295. BOX 17-15 Clinical Signs and Symptoms of Liver Disease
  2296. Cardiac
  2297. Dermatological
  2298. Electrolytes
  2299. Endocrine
  2300. Fluid Alterations
  2301. Gastrointestinal
  2302. Hematological
  2303. Immune System
  2304. Neurological
  2305. Pulmonary
  2306. Renal
  2307. Impaired Metabolic Processes.
  2308. Impaired Bile Formation and Flow.
  2309. Nursing Diagnoses
  2310. NURSING CARE PLAN for the Patient with Hepatic Failure
  2311. NURSING DIAGNOSIS
  2312. PATIENT OUTCOMES
  2313. Adequate fluid volume
  2314. NURSING DIAGNOSIS
  2315. PATIENT OUTCOMES
  2316. Adequate nutrition
  2317. NURSING DIAGNOSIS
  2318. PATIENT OUTCOMES
  2319. Effective breathing
  2320. NURSING DIAGNOSIS
  2321. PATIENT OUTCOMES
  2322. Normal thought processes
  2323. Medical and Nursing Interventions
  2324. Diagnostic Tests
  2325. Supportive Therapy
  2326. LABORATORY ALERTS
  2327. Liver Failure5
  2328. From Chernecky, C. C., & Berger, B. J. (2008). Laboratory tests and diagnostic procedures (5th ed.). Philadelphia: Saunders.
  2329. Support for the Failing Liver
  2330. Treatment of Complications
  2331. Ascites.
  2332. BOX 17-16 Physiological Effects of Abdominal Compartment Syndrome
  2333. Cardiovascular
  2334. Respiratory
  2335. Hepatic and Renal
  2336. Gastrointestinal
  2337. Neurological
  2338. Portal Systemic Encephalopathy.
  2339. FIGURE 17-12 The Denver shunt. Percutaneous placement of both the venous and peritoneal catheters of a Denver Ascites Shunt. Venous catheter placement into the (A) subclavian and (B) internal jugular vein.
  2340. BOX 17-17 Stages of Portal Systemic Encephalopathy
  2341. Stage 1
  2342. Stage 2
  2343. Stage 3
  2344. Stage 4
  2345. Hepatorenal Syndrome.
  2346. Patient Outcomes
  2347. CASE STUDY
  2348. QUESTIONS
  2349. SUMMARY
  2350. CRITICAL THINKING QUESTIONS
  2351. REFERENCES
  2352. CHAPTER 18 Endocrine Alterations
  2353. INTRODUCTION
  2354. Changes in the Endocrine System in Critical Illness
  2355. Disease States of the Endocrine System
  2356. HYPERGLYCEMIA IN THE CRITICALLY ILL PATIENT
  2357. FIGURE 18-1 Feedback system for cortisol regulation.
  2358. Achieving Glycemic Control
  2359. Hypoglycemia as a Preventable Adverse Effect of Glucose Management
  2360. GERIATRIC CONSIDERATIONS
  2361. PANCREAS
  2362. ADRENAL
  2363. THYROID
  2364. PITUITARY
  2365. The Diabetic Patient in the Critical Care Unit
  2366. Box 18-1 Risk Factors for the Development of Hyperglycemia in the Critically Ill Patient16,19
  2367. Box 18-2 Key Components of a Glucose Management Protocol
  2368. PANCREATIC ENDOCRINE EMERGENCIES
  2369. Review of Physiology
  2370. TABLE 18-1 Types of Insulin
  2371. Box 18-3 Physiological Activity of Insulin
  2372. Carbohydrate Metabolism
  2373. Fat Metabolism
  2374. Protein Metabolism
  2375. Effects of Aging
  2376. Hyperglycemic Crises
  2377. Pathogenesis
  2378. CLINICAL ALERT
  2379. Metabolic Syndrome
  2380. GENETICS
  2381. Type 2 Diabetes Mellitus: A Complex Disease with Complex Genetics
  2382. REFERENCES
  2383. FIGURE 18-2 Pathophysiology of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS).
  2384. Etiology of Diabetic Ketoacidosis.
  2385. Box 18-4 Factors Leading to Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State
  2386. Common Factors
  2387. Medications
  2388. DKA-Specific Factors
  2389. HHS-Specific Factors
  2390. Etiology of Hyperosmolar Hyperglycemic State.
  2391. Pathophysiology of Diabetic Ketoacidosis
  2392. FIGURE 18-3 Intracellular/extracellular shifts in hyperglycemic crises. DKA, Diabetic ketoacidosis.
  2393. Box 18-5 Calculation for Anion Gap
  2394. Pathophysiology of Hyperosmotic Hyperglycemic State
  2395. Box 18-6 HHS and Other Synonymous Acronyms
  2396. Assessment
  2397. Clinical Presentation.
  2398. TABLE 18-2 Manifestations of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State
  2399. Laboratory Evaluation.
  2400. LABORATORY ALERTS
  2401. Pancreatic Endocrine Disorders
  2402. Nursing and Medical Interventions
  2403. EVIDENCE-BASED PRACTICE
  2404. PROBLEM
  2405. QUESTION
  2406. REFERENCES
  2407. EVIDENCE
  2408. IMPLICATIONS FOR NURSING
  2409. Respiratory Support.
  2410. Fluid Replacement.
  2411. Insulin Therapy.
  2412. Box 18-7 Signs and Symptoms of Fluid Overload
  2413. Electrolyte Management.
  2414. Treatment of Acidosis.
  2415. Patient and Family Education.
  2416. Patient Outcomes
  2417. NURSING CARE PLAN for the Patient with Hyperglycemic Crisis
  2418. NURSING DIAGNOSIS
  2419. PATIENT OUTCOMES
  2420. Normal respiratory rate and pattern
  2421. NURSING DIAGNOSIS
  2422. PATIENT OUTCOMES
  2423. Adequate fluid volume status
  2424. NURSING DIAGNOSIS
  2425. PATIENT OUTCOMES
  2426. Effective therapeutic management of diabetes
  2427. Hypoglycemia
  2428. Pathophysiology
  2429. Etiology
  2430. FIGURE 18-4 Pathophysiology of hypoglycemia.
  2431. Assessment
  2432. Clinical Presentation.
  2433. Box 18-8 Causes of Hypoglycemia
  2434. Excess Insulin or Oral Hypoglycemics
  2435. Decreased Oral, Enteral, or Parenteral Intake
  2436. Underproduction of Glucose
  2437. Too Rapid Utilization of Glucose
  2438. TABLE 18-3 Signs and Symptoms of Hypoglycemia
  2439. Laboratory Evaluation.
  2440. Nursing Diagnoses
  2441. Box 18-9 Treatment of Hypoglycemia
  2442. Mild Hypoglycemia
  2443. Moderate Hypoglycemia
  2444. Severe Hypoglycemia
  2445. Nursing and Medical Interventions
  2446. Box 18-10 Sources of 15 Grams of Carbohydrates
  2447. Patient Outcomes
  2448. ACUTE AND RELATIVE ADRENAL INSUFFICIENCY
  2449. Etiology
  2450. Box 18-11 Causes of Adrenal Insufficiency
  2451. Primary
  2452. Secondary
  2453. Box 18-12 Therapeutic Uses of Corticosteroids
  2454. Replacement Therapy in Patients with Primary or Secondary Adrenal Cortical Insufficiency
  2455. Review of Physiology
  2456. Box 18-13 Physiological Effects of Glucocorticoids (Cortisol)
  2457. Pathophysiology
  2458. FIGURE 18-5 Physiology of aldosterone release.
  2459. Assessment
  2460. Clinical Presentation
  2461. Box 18-14 Risk Factor Analysis for Adrenal Crisis
  2462. Cardiovascular System.
  2463. Neurological System.
  2464. FIGURE 18-6 Pathophysiological effects of adrenal insufficiency. BUN, Blood urea nitrogen; ECG, electrocardiogram; MSH, melanocyte-stimulating hormone.
  2465. Gastrointestinal System.
  2466. Genitourinary System.
  2467. Box 18-15 Progressive Signs of Chronic Adrenal Insufficiency
  2468. Laboratory Evaluation
  2469. LABORATORY ALERTS
  2470. Adrenal Disorders
  2471. Nursing Diagnoses
  2472. Box 18-16 Cosyntropin Stimulation Test
  2473. Standard Method
  2474. Test Response
  2475. Nursing and Medical Interventions
  2476. Fluid and Electrolyte Replacement
  2477. Hormonal Replacement
  2478. PHARMACOLOGY TABLE 18-4 Medications Used to Treat Adrenal Crisis
  2479. Box 18-17 Treatment of Adrenal Crisis
  2480. Identify and Treat Precipitating Event
  2481. Replace Fluid and Electrolytes
  2482. Hormonal Replacement
  2483. Patient Education
  2484. Patient and Family Education
  2485. THYROID GLAND IN CRITICAL CARE
  2486. Review of Physiology
  2487. Box 18-18 Physiological Effect of Thyroid Hormones
  2488. Major Effects
  2489. Other Effects
  2490. FIGURE 18-7 Feedback systems for thyroid hormone regulation.
  2491. Box 18-19 Causes of Blockage of Conversion from Thyroxine to Triiodothyronine
  2492. Effects of Aging
  2493. Thyroid Function in the Critically Ill
  2494. THYROID CRISES
  2495. Etiology
  2496. Box 18-20 Causes of Hyperthyroidism
  2497. Most Common
  2498. Other Causes
  2499. Rare Causes
  2500. Associated with Other Disorders*
  2501. Thyrotoxic Crisis (Thyroid Storm)
  2502. Pathophysiology
  2503. Box 18-21 Causes of Hypothyroidism
  2504. Primary Thyroid Disease
  2505. Secondary (Pituitary) or Tertiary (Hypothalamus) Disease
  2506. Assessment
  2507. Clinical Presentation
  2508. Thermoregulation Disturbances.
  2509. Neurological Disturbances.
  2510. Cardiovascular Disturbances.
  2511. Box 18-22 Progressive Signs of Hyperthyroidism
  2512. Pulmonary Disturbances.
  2513. Gastrointestinal Disturbances.
  2514. Musculoskeletal Disturbances.
  2515. Laboratory Evaluation.
  2516. Nursing Diagnoses
  2517. TABLE 18-5 Thyroid Crises
  2518. Nursing and Medical Interventions
  2519. Box 18-23 Treatment of Thyroid Storm
  2520. Antagonize Peripheral Effects of Thyroid Hormone
  2521. Inhibit Hormone Biosynthesis
  2522. Block Thyroid Hormone Release
  2523. Give 1-2 Hours after Proplylthiouracil or Methimazole Loading Dose
  2524. Secondary Options
  2525. Supportive Therapy
  2526. Identify and Treat Precipitating Cause
  2527. Patient and Family Education
  2528. LABORATORY ALERTS
  2529. Thyroid Disorders
  2530. Antagonism of Peripheral Effects of Thyroid Hormones.
  2531. Inhibition of Thyroid Hormone Biosynthesis.
  2532. Blockage of Thyroid Hormone Release.
  2533. Supportive Care.
  2534. Patient and Family Education.
  2535. Patient Outcomes
  2536. Myxedema Coma
  2537. Pathophysiology
  2538. Etiology
  2539. Assessment
  2540. Clinical Presentation.
  2541. Cardiovascular Disturbances.
  2542. Box 18-24 Progressive Signs of Hypothyroidism
  2543. Pulmonary Disturbances.
  2544. Neurological Disturbances.
  2545. Skeletal Muscle Disturbances.
  2546. Laboratory Evaluation.
  2547. Nursing Diagnoses
  2548. Nursing and Medical Interventions
  2549. Box 18-25 Treatment of Myxedema Coma
  2550. Thyroid Replacement.
  2551. Fluid and Electrolyte Restoration.
  2552. Supportive Care.
  2553. Patient and Family Education.
  2554. Patient Outcomes
  2555. ANTIDIURETIC HORMONE DISORDERS
  2556. Review of Physiology
  2557. FIGURE 18-8 Hypothalamic–posterior pituitary system.
  2558. Diabetes Insipidus
  2559. Etiology
  2560. Box 18-26 Causes of Diabetes Insipidus
  2561. Antidiuretic Hormone Deficiency (Neurogenic Diabetes Insipidus)
  2562. Antidiuretic Hormone Insensitivity (Nephrogenic Diabetes Insipidus)
  2563. Secondary Diabetes Insipidus
  2564. Pathophysiology
  2565. FIGURE 18-9 Physiology of antidiuretic hormone (ADH) release. BP, Blood pressure.
  2566. TABLE 18-6 Electrolyte and Fluid Findings in ADH Disorders
  2567. Assessment
  2568. Clinical Presentation.
  2569. Laboratory Evaluation.
  2570. Nursing Diagnoses
  2571. Nursing and Medical Interventions
  2572. Volume Replacement.
  2573. Hormone Replacement.
  2574. LABORATORY ALERTS
  2575. Pituitary Disorders
  2576. Nephrogenic Diabetes Insipidus.
  2577. Patient and Family Education.
  2578. Patient Outcomes
  2579. Syndrome of Inappropriate Antidiuretic Hormone
  2580. Etiology
  2581. Pathophysiology
  2582. Assessment
  2583. Clinical Presentation.
  2584. Box 18-27 Causes of Syndrome of Inappropriate Antidiuretic Hormone
  2585. Ectopic Antidiuretic Hormone Production
  2586. Central Nervous System Disorders
  2587. Drugs
  2588. Positive-Pressure Ventilation
  2589. Central Nervous System.
  2590. Gastrointestinal System.
  2591. Cardiovascular System.
  2592. Pulmonary System.
  2593. Laboratory Evaluation.
  2594. Nursing Diagnoses
  2595. Nursing and Medical Interventions
  2596. Fluid Balance.
  2597. Box 18-28 Treatments for Chronic or Resistant Syndrome of Inappropriate Antidiuretic Hormone
  2598. Nursing.
  2599. Patient and Family Education.
  2600. Patient Outcomes
  2601. CASE STUDY
  2602. QUESTIONS
  2603. SUMMARY
  2604. CRITICAL THINKING QUESTIONS
  2605. REFERENCES
  2606. CHAPTER 19 Trauma and Surgical Management
  2607. INTRODUCTION
  2608. TRAUMA DEMOGRAPHICS
  2609. SYSTEMS APPROACH TO TRAUMA CARE
  2610. Trauma System
  2611. Levels of Trauma Care
  2612. Trauma Continuum
  2613. Injury Prevention
  2614. Trauma Team Concept
  2615. Box 19-1 Multidisciplinary Trauma Team
  2616. Prehospital Care and Transport
  2617. Trauma Triage
  2618. Disaster and Mass Casualty Management
  2619. MECHANISMS OF INJURY
  2620. Blunt Trauma
  2621. Penetrating Trauma
  2622. FIGURE 19-1 Potential sites of blunt trauma injury in unrestrained passenger and driver in a motor vehicle crash. A, Unrestrained passenger in front seat. B, Unrestained driver. C, Lateral impact collision.
  2623. Blast Injuries
  2624. EMERGENCY CARE PHASE
  2625. Initial Patient Assessment
  2626. Primary and Secondary Survey
  2627. TABLE 19-1 Primary Survey: ABCDE
  2628. RESUSCITATION PHASE
  2629. Establishing Airway Patency
  2630. TABLE 19-2 Secondary Survey
  2631. Maintaining Effective Breathing
  2632. Maintaining Circulation
  2633. TABLE 19-3 Specific Interventions for Ineffective Breathing Patterns
  2634. Diagnostic Testing
  2635. Adequacy of Resuscitation
  2636. Fluid Resuscitation
  2637. TABLE 19-4 Responses to Initial Fluid Resuscitation*
  2638. EVIDENCE-BASED PRACTICE
  2639. PROBLEM
  2640. Question
  2641. REFERENCE
  2642. EVIDENCE
  2643. IMPLICATIONS FOR NURSING
  2644. Assessment of Neurological Disabilities
  2645. Exposure and Environmental Considerations
  2646. FIGURE 19-2 Medi-Temp Blood and Fluid Warmer.
  2647. TABLE 19-5 Rewarming Strategies
  2648. ASSESSMENT AND MANAGEMENT OF SPECIFIC ORGAN INJURIES
  2649. Thoracic Injuries
  2650. Cardiac Tamponade
  2651. Cardiac Contusion
  2652. Aortic Disruption
  2653. Tension Pneumothorax
  2654. Hemothorax
  2655. Open Pneumothorax
  2656. Pulmonary Contusion
  2657. Rib Fractures and Flail Chest
  2658. Abdominal Injuries
  2659. Musculoskeletal Injuries
  2660. FIGURE 19-3 Common types of fractures.
  2661. Complications
  2662. Compartment Syndrome.
  2663. Rhabdomyolysis.
  2664. Deep Vein Thrombosis.
  2665. Fat Embolism Syndrome.
  2666. CRITICAL CARE PHASE
  2667. Damage-Control Surgery
  2668. Postoperative Management
  2669. GERIATRIC CONSIDERATIONS
  2670. SPECIAL CONSIDERATIONS AND POPULATIONS
  2671. Effects of Aging
  2672. Alcohol and Drug Abuse
  2673. Box 19-2 Signs and Symptoms of Alcohol Withdrawal
  2674. Family and Patient Coping
  2675. REHABILITATION
  2676. CASE STUDY
  2677. QUESTIONS
  2678. SUMMARY
  2679. CRITICAL THINKING QUESTIONS
  2680. REFERENCES
  2681. CHAPTER 20 Burns
  2682. INTRODUCTION
  2683. REVIEW OF ANATOMY AND PHYSIOLOGY OF THE SKIN
  2684. Effects of Aging
  2685. FIGURE 20-1 Anatomy of the skin.
  2686. MECHANISMS OF INJURY
  2687. Thermal Injury
  2688. Chemical Injury
  2689. Electrical Injury
  2690. TABLE 20-1 Types of Smoke Inhalation Injury
  2691. Inhalation Injury
  2692. Carbon Monoxide Poisoning
  2693. TABLE 20-2 Carboxyhemoglobin
  2694. Injury Above the Glottis
  2695. CLINICAL ALERT
  2696. Clinical Indicators of Inhalation Injury
  2697. Injury Below the Glottis
  2698. BURN CLASSIFICATION AND SEVERITY
  2699. CLINICAL ALERT
  2700. Guidelines for Burn Center Referral
  2701. Depth of Injury
  2702. TABLE 20-3 Depth of Burn Injury
  2703. Extent of Injury
  2704. PHYSIOLOGICAL RESPONSES TO BURN INJURY
  2705. FIGURE 20-2 Zones of thermal injury.
  2706. FIGURE 20-3 The rule of nines. TBSA, Total body surface area. EXAMPLE: An adult with superficial burns to the face and partial-thickness burns to the lower half of the right arm, entire left arm, and chest: 4.5% (lower right arm) + 9% (entire left arm) + 9% (chest or upper anterior trunk) = 22.5% TBSA (the superficial burns to the face are not included in the %TBSA calculation).
  2707. FIGURE 20-4 Burn estimate and diagram. Ant, Anterior; post, posterior; L, left; R, right; R. U., right upper; R. L., right lower; L. U., left upper; L. L., left lower.
  2708. FIGURE 20-5 Overview of physiological changes that occur after acute burn injury. TBSA, Total body surface area; TNF, tumor necrosis factor.
  2709. FIGURE 20-6 Pathophysiology of extensive burn injury. *A response associated with burn injury greater than 20% to 25% total body surface area (%TBSA). CO, Cardiac output; H2O, water; Hct, hematocrit; SVR, systemic vascular resistance; UO, urinary output.
  2710. FIGURE 20-7 Burn edema and shock development. H2O, Water; K, potassium; Na, sodium.
  2711. Cardiovascular Response
  2712. Host Defense Mechanisms
  2713. Pulmonary Response
  2714. Renal Response
  2715. Gastrointestinal Response
  2716. Metabolic Response
  2717. PHASES OF BURN CARE ASSESSMENT AND COLLABORATIVE INTERVENTIONS
  2718. Resuscitative Phase: Prehospital
  2719. Primary Survey
  2720. NURSING CARE PLAN for Resuscitative and Acute Care Phases of Major Burn Injury
  2721. NURSING DIAGNOSIS
  2722. PATIENT OUTCOMES
  2723. Adequate airway clearance and gas exchange
  2724. NURSING DIAGNOSIS
  2725. Adequate fluid volume
  2726. PATIENT OUTCOMES
  2727. NURSING DIAGNOSIS
  2728. PATIENT OUTCOME
  2729. Normothermia
  2730. NURSING DIAGNOSIS
  2731. PATIENT OUTCOMES
  2732. Adequate tissue perfusion
  2733. NURSING DIAGNOSIS
  2734. PATIENT OUTCOMES
  2735. Relief of pain
  2736. NURSING DIAGNOSIS
  2737. PATIENT OUTCOMES
  2738. Absence of infection
  2739. NURSING DIAGNOSES
  2740. PATIENT OUTCOMES
  2741. Absence of injury and adequate nutrition
  2742. NURSING DIAGNOSIS
  2743. PATIENT OUTCOMES
  2744. Physical mobility
  2745. NURSING DIAGNOSIS
  2746. PATIENT OUTCOMES
  2747. Effective coping
  2748. Stopping the Burning Process.
  2749. FIGURE 20-8 Major burn injury: primary survey. BP, Blood pressure; CPR, cardiopulmonary resuscitation.
  2750. Airway (with Cervical Spine Precautions).
  2751. Breathing.
  2752. Circulation.
  2753. Secondary Survey
  2754. FIGURE 20-9 Major burn injury: secondary survey. ABG, Arterial blood gas; ECG, electrocardiogram; IV, intravenous; LR, lactated Ringer’s solution.
  2755. Resuscitative Phase: Emergency Department and Critical Care Burn Center
  2756. Transfer to a Burn Center
  2757. Primary Survey
  2758. Airway.
  2759. Breathing.
  2760. FIGURE 20-10 Burn center transfer form. ABG, Arterial blood gas; CIRC, circulatory; CO, carbon monoxide; ET, endotracheal tube; GI/GU, gastrointestinal/genitourinary; HEENT, head, eyes, ears, nose, throat; NG, nasogastric tube; O2, oxygen.
  2761. FIGURE 20-11 Facial edema.
  2762. FIGURE 20-12 Escharotomy.
  2763. Circulation
  2764. Fluid Resuscitation.
  2765. BOX 20-1 Burn Fluid Resuscitation Formula
  2766. First 24 Hours Administer
  2767. ABLS Consensus Formula (Based on the Parkland Formula)
  2768. Second 24 Hours Administer
  2769. Parkland Formula
  2770. End Point Monitoring.
  2771. EVIDENCE-BASED PRACTICE
  2772. PROBLEM
  2773. REFERENCES
  2774. EVIDENCE
  2775. IMPLICATIONS FOR NURSING
  2776. Peripheral Circulation.
  2777. Secondary Survey
  2778. Cardiovascular System.
  2779. Neurological Status.
  2780. Renal Status.
  2781. Gastrointestinal System.
  2782. Integumentary System.
  2783. Blood and Electrolytes.
  2784. Acute Care Phase: Critical Care Burn Center
  2785. LABORATORY ALERTS
  2786. Respiratory System
  2787. Cardiovascular System
  2788. Neurological Status
  2789. Renal Status
  2790. Gastrointestinal System
  2791. Integumentary System
  2792. Blood and Electrolytes
  2793. SPECIAL CONSIDERATIONS AND AREAS OF CONCERN
  2794. Burns of the Face
  2795. Burns of the Ears
  2796. Burns of the Eyes
  2797. Burns of the Hands, Feet, or Major Joints
  2798. Burns of the Genitalia and Perineum
  2799. Electrical Injury
  2800. Chemical Injury
  2801. BOX 20-2 Manifestations and Complications of Electrical Injury
  2802. Abuse and Neglect
  2803. FIGURE 20-13 Child abuse by hot water immersion. The thigh burn wound edges have a clear demarcation line (are in a straight line), and there are no splash marks. The parents delayed seeking medical treatment for the child’s burns until 3 days after injury (note the dry, crusty appearance of the wounds). The child also had a forearm fracture and multiple areas of bruising on the body.
  2804. PAIN CONTROL
  2805. INFECTION CONTROL
  2806. WOUND MANAGEMENT
  2807. Wound Care
  2808. Topical Agents and Dressings
  2809. PHARMACOLOGY TABLE 20-4 Topical Antimicrobial Agents for Burn Wound Management
  2810. TABLE 20-5 Biological and Biosynthetic Dressings
  2811. Surgical Excision and Grafting
  2812. FIGURE 20-14 A, Vacuum-assisted closure (VAC) device. B, The device creates a negative-pressure dressing to decompress edematous interstitial spaces and to increase local perfusion, help draw wound edges closed uniformly, remove wound fluid, and provide a closed, moist healing environment.
  2813. FIGURE 20-15 Excision and autografting. A, Surgical debridement (excision) with meshed autograft placement in the operating room. B, Meshed autograft postoperative day 2. C, Comparison of sheet autograft (on hand) versus meshed autograft (on forearm) 3 weeks postoperatively. Use of meshed autograft allows larger body surface area coverage, but it also typically leads to more scarring and a less cosmetically pleasing appearance.
  2814. TABLE 20-6 Autograft Skin: Nursing Implications
  2815. NUTRITIONAL CONSIDERATIONS
  2816. TABLE 20-7 Types of Donor Site Dressings
  2817. PSYCHOSOCIAL CONSIDERATIONS
  2818. GERIATRIC CONCERNS
  2819. BOX 20-3 Stages of Postburn Psychological Adaptation
  2820. Survival Anxiety
  2821. Search for Meaning
  2822. Investment in Recuperation
  2823. Investment in Rehabilitation
  2824. Reintegration of Identity
  2825. GERIATRIC CONSIDERATIONS
  2826. NONBURN INJURY
  2827. Severe Exfoliative Disorders
  2828. Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, Erythema Multiforme
  2829. Staphylococcal Scalded Skin Syndrome
  2830. Necrotizing Soft Tissue Infections
  2831. DISCHARGE PLANNING
  2832. BURN PREVENTION
  2833. BOX 20-4 Strategies for Preventing Burn Injuries
  2834. Cook with Care
  2835. Hot Liquids Cause Scalds
  2836. Home Precautions
  2837. Fire Extinguishers and Smoke Detectors
  2838. Occupation-Related Precautions
  2839. CASE STUDY
  2840. QUESTIONS
  2841. SUMMARY
  2842. CRITICAL THINKING QUESTIONS
  2843. REFERENCES

People also search: